ROBIN FARIAS-EISNER, MD PHD MBA FACOG

Professor and Chairman,
Department of Obstetrics and Gynecology at CUSOM
Associate Dean, Women's Health at Creighton University School of Medicine (CUSOM)
Executive Medical Director, Women's Health
Chief Academic Officer
Director, Henry Lynch Hereditary Cancer Center at CUSOM
Charles F. and Mary C. Heider Endowed Chair in Cancer Research, Creighton University

Professor Emeritus and Distinguished Research Professor, David Geffen School of Medicine, UCLA

Creighton University Medical Center - Bergan Mercy
Education Building
Department of Obstetrics and Gynecology
7710 Mercy Road, Suite 602
Omaha, NE 68124

CURRICULUM VITAE

ACADEMIC EXECUTIVE RESUME

PERSONAL STATEMENT

My unique medical education at the Royal College of Surgeons in Ireland (RCSI) established my commitment to the concept of Physical Diagnosis which is solidly based in a humanistic osteopathic tradition dating back to RCSI's founding British Royal Charter in 1784. Building upon a highly desirable humanistic philosophy, my healthcare teams have created Centers of Excellence during my 3-decade tenure at UCLA, and now at the Creighton University School of Medicine (CUSOM).

In an effort to lend insight into my professional and personal mantra, I share three recognitions. Most recently, my dedication to humanism and academic healthcare leadership was graciously recognized May 7th, 2021, by the Creighton University School of Medicine (CUSOM) with the national Golden Apple Award recognizing teaching, compassionate patient care, and integrity. I was blessed to receive similar recognition at UCLA which honored Humanism and Academic Leadership with the prestigious Serge & Yvette Dadone award, a highly distinguished School of Medicine Faculty Patient Care and Clinical Teaching Award conferred upon a single Faculty, and only once per career, who has demonstrated unapparelled excellence in Patient Care and Clinical Teaching at the David Geffen School of Medicine (DGSOM) at UCLA.

One year later, I was again blessed to have received the highest award from the DGSOM, the acclaimed and coveted Sherman M. Mellinkoff Dean's Award, bestowed upon a clinician-scientist leader who exemplifies the art of medicine through teaching, integrity, character, and physician-patient relationships, representing a Life Time Achievement award, 33 awards of which have been issued since the inception of the School of Medicine at UCLA in 1955.

Not surprising, I am attracted to the humanistic and osteopathic model exemplified in the traditions at Western University, health Sciences. I commend the distinguished leaders of the University for the successful quest to achieve transformative health, hence, to create a healthy society for present and future generations.

Throughout my career, in close alignment with Western University philosophy, I have championed the implementation of core values that embody humanism via the integration of team, excellence, inclusivity, flexibility, compassion, empathy, integrity, trust, and respect. Likewise, as will be evident in your review of my Curriculum Vitae, I have embraced and implemented team-driven and pioneering growth in medicine and science.

I would consider my academic educational leadership career to be one that characterizes me as an effective fund-raiser, innovator, administrator, surgeon-scientist, entrepreneur, pioneer, consensus builder and academician dedicated to the promotion of health and to the aforementioned values. I have been committed to the creation of robust and sustainable academic business enterprises, from the creation of clinical Centers of Excellence to the establishment of a highly productive Farias-Eisner Laboratory (the Center for Biomarker Discovery and Women's Cancer Research) at DGSOM, at UCLA; and now at the Creighton University School of Medicine (CUSOM), pioneering the discovery of novel diagnostic platforms (e.g. serum biomarkers – Multivariate Index Assays) and new targeted and immunotherapies (e.g. dual domain mimetic peptides - HM1010) for the treatment of chemotherapy refractory gynecologic malignancies.

Professional Leadership Mantra – 20 top priorities

1) Promote communication through refined interpersonal communicative skills;
2) Inspire and engage all those associated with the University (e.g. trustees, students, faculty, staff, alumni, parents, families, friends, community, etc.);
3) Stimulate, endorse and advocate for the concepts of diversity, equity and inclusion: demonstrated experience supporting and implementing diversity, equity and inclusion initiatives;
4) Empower the learner, and promote high quality teaching, research and education across the health sciences;
5) Demonstrate a high-quality skill set in the administration of the organization's operations (e.g. choreographing planning, organization, etc.);

6) Implement an inclusive, energizing, consensus building, collegial, collaborative and unifying style that motivates and inspires the University community;
7) Galvanize the University greater community in an environment of essential shared governance (e.g. University of California, Creighton University);
8) Embrace an entrepreneurial spirit and business-driven visionary growth, development and advancement;
9) Mentor and promote present and future members of the senior executive leadership team through prudent guidance;
10) Prioritize creative and novel philanthropic growth and advancement models through effective fundraising efforts (e.g. University of California, Creighton University);
11) High level fiscal responsibility, a primary focus on "Revenue Diversity", stewardship, acumen, experience and track record of success (e.g. University of California, Creighton University);
12) A focus on superb interpersonal skills, positive energy, communicative skills, consensus-building, and team building through "Interprofessionalism" through an interprofessional, collaborative and collegial approach in all missions and at all levels of the University;
13) Emphasis on a culture of transparency, honesty, integrity, and through highly positive optics;
14) High energy, inspiring, high visibility, strong work ethic, and engaging attitude;
15) Lives by the work place triad: Compassion, Patience and Humility, and hence creation of partnerships in education, healthcare, research, and community missions;
16) Priority: community engagement, interaction, development, and advancement and the identification and growth of new and existing sources of revenue (e.g. > 20% of revenue from non-tuition sources);
17) Attention to mentorship, nurturing of the careers of all within the University environs through the development of a shared vision and a vibrant strategic plan for the institution's future promoting collaboration, collegiality, and a strong ethos pervasive throughout the campus;
18) A clear focus on innovation, creativity, discovery, entrepreneurialism and business-driven optics;
19) Promotion of diversity, health equity, equality, inclusivity, the elimination of healthcare disparities and the enhancement of healthcare knowledge;
20) Promotion of the principles of shared governance (e.g. University of California, Creighton University) and integration and promotion of the University DNA in all aspects of the Institution;

Three most recent successful entrepreneurial and business-driven scientific biomedical initiatives:

1) Co-Inventor – Farias-Eisner laboratory - Multivariate Index Assays/OVA-1 plus assay, applied to the clinical differentiation of benign from malignant ovarian masses, the Intellectual Property of which was licensed from UCLA, and commercialized by Quest Laboratories;

2) Co-Founder CUE Health - Biotech startup Cue Health is partnered with the U.S. Department of Health and Human Service's Biomedical Advanced Research and Development Authority (BARDA) and has developed a highly accurate handheld nucleic acid-based (RT-PCR) molecular test that pairs cartridge-like test kits with a compact and connected mini lab device which transmits results to a personalized app-based health dashboard. Recent trials demonstrated sensitive (100%) and specific (100%) at >20 copies/ml. The highly accurate point-of-care test can detect the presence of a multitude of infectious agents, including live SARS-CoV-2 novel coronavirus that causes COVID-19. CUE Health has the capacity to detect HIV, Respiratory Syncytial Virus, Influenza A&B, Sexually Transmitted Diseases, etc.). Pre-IPO stage (projected IPO – 6/2021);
3) Co-Inventor - Farias-Eisner laboratory - New Drug Discovery - HM1010 functional mimetic chimera peptide developed as an anti-cancer drug with efficacy against other pro-inflammatory diseases (e.g. endometriosis, dry macular degeneration, Alzheimer's disease, CAD).

I have dedicated my career to the creation of successful academic healthcare enterprises through the establishment of quality clinical, educational, research, and community engagement programs, in the area of women's healthcare. I have been committed to the elimination of healthcare disparities nationally (e.g. NIH/NCI).

LICENSURES

- State of California License
- State of Nebraska License
- State of Illinois License
- DEA

BOARD CERTIFICATION

- American Board of Emergency Medicine
- American Board of Obstetrics & Gynecology

- American Subspecialty Board in Gynecologic Oncology

FELLOW

- Fellow American College of Obstetricians and Gynecologist

ACADEMIC POSITION

Creighton University School of Medicine (CUSOM), Omaha, NE

Professor and Chair in the Department of Obstetrics and Gynecology

Associate Dean Women's Health

Director, Henry Lynch Hereditary Cancer Center

Charles F. and Mary C. Heider Endowed Chair in Cancer Research

Executive Medical Director, Women's Health

Chief Academic Officer

University of California at Los Angeles (UCLA), Los Angeles, CA
David Geffen School of Medicine at UCLA (DGSOM)

Professor Emeritus and Distinguished Research Professor

EDUCATION

University of California at Los Angeles (UCLA), Los Angeles, CA
Bachelor of Science – Biochemistry (1975)

Royal College of Surgeons in Ireland, Dublin, Ireland
Medical Doctor Degree BAO M. B., LRSCI (1981)

University of Illinois/University of Chicago, Chicago, Illinois
Residency in Emergency Medicine/Critical Care (1985)

University of Illinois/University of Chicago, Chicago, Illinois
Faculty in Emergency Medicine/Critical Care (1986)

University of California at Los Angeles (UCLA), Los Angeles, CA
Residency in Obstetrics and Gynecology (1990)

University of California at Los Angeles (UCLA), Los Angeles, CA
Fellowship in Obstetrics and Gynecology (1992)

University of California at Los Angeles (UCLA), Los Angeles, CA
Physician – Scientist PhD Molecular Biology program (1996)

STAR (Specialty Training in Advanced Research) PROGRAM at UCLA
Molecular Biology Institute, at UCLA
David Geffen School of Medicine, at UCLA
PhD - Molecular Biology

Pepperdine University, Los Angeles, CA
Graziadio School of Business management
Health Care Administration and Business Management Program (2015)
Management Executive Program
MBA

SELECTED HONORS AND AWARDS

University of California at Los Angeles (UCLA), Department of Obstetrics and Gynecology, Los Angeles, CA

1990	Chief Resident Award
1996-2019	UCLA Faculty Outstanding Teaching Award x 12 annual awards
1996-1999	Physician-Scientist STAR Award
1999-2000	STAR (Specialty Training Advanced Research) Faculty Award

University of California at Los Angeles (UCLA), Dean's Office David Geffen School of Medicine at UCLA, Los Angeles, CA

2011	Prestigious Serge & Yvette Dadone – Distinguished Faculty Patient Care and Clinical Teaching Award - Recipient 2011- conferred upon a single Faculty (per annum), and only once per career, who has demonstrated unapparelled excellence in Patient Care and Clinical Teaching at DGSOM at UCLA
2012	Sherman M. Mellinkoff Dean's Award at DGSOM – Bestowed upon a clinician-scientist who exemplifies the art of medicine through teaching, integrity, character, and physician-patient relationships – (Life Time Achievement award – only 33 awards given since the inception of the School of Medicine);

U.S. Department of Defense, *Washington, D.C.*

2006-2010	Merit 1 award; Department of Veteran Affairs

National Institutes of Health – National Cancer Institute, *Bethesda, MD*

2000-2002	NIH R03 Award
2009-2020	NIH/NCI CA143930 U54 Award

Research Foundations Awards,

1989	Berlix Research Foundation; Research Award
2000-2003	Liz Tilberis Ovarian Cancer Scholars Award
2008-2018	Carl and Roberta Deutsch Family Foundation Award
2018-2021	Annenberg Family Foundation Award

Creighton University – School of Medicine, Omaha, NE

2019 Charles F. & Mary C. Heider Endowed Chair in Cancer Research – distinguished award for innovative cancer research

2021 Golden Apple Award – Distinguished award honoring teaching, compassionate patient care, and integrity

LEADERSHIP AND PROGRAM-BUILDING EXPERIENCE

University of Illinois/University of Chicago Emergency Medicine, School of Medicine, Chicago, Illinois

1981-1986 Residency/ Faculty: Emergency Medicine/Critical Care

University of California at Los Angeles (UCLA), Dean's Office David Geffen School of Medicine at UCLA, Los Angeles, CA

1986-1990 Residency: Obstetrics and Gynecology; UCLA School of Medicine

1990-1992 Clinical Instructor UCLA School of Medicine; Fellowship: Gynecologic Oncology

1992-1999 Assistant Professor; Department of Obstetrics and Gynecology; UCLA School of Medicine

1993 Parke-Davis-CREOG/APGO

1996-1999 Physician-Scientist STAR program; UCLA School of Medicine; Molecular Biology Institute

1998-present Director of Gynecologic Oncology; UCLA School of Medicine-Westside Veteran Admin. Hospital

1999-2004 Associate Professor; Department of Obstetrics and Gynecology; David Geffen School of Medicine at UCLA

2003-present Director: Center for biomarker Discovery and Research – Women's Cancers at UCLA

2004-present Professor; Department of Obstetrics and Gynecology; David Geffen School of Medicine at UCLA

2006-2019 Director; Gynecology and Gynecologic Oncology; David Geffen School of Medicine at UCLA

2006-2019 co-Director; Women's Cancer Program; Jonsson Comprehensive Cancer Center

2008-present American Board of Obstetrics and Gynecology Examiner

2009-2019 Vice Chair, Administration; Department of Obstetrics and Gynecology at UCLA

2015-present NIH/NICHD U54 Study Section; NIH

2019-present Professor Emeritus, Department of Obstetrics and Gynecology; David Geffen School of Medicine at UCLA

2019-present Distinguished Research Professor; Department of Obstetrics and Gynecology; David Geffen School of Medicine at UCLA

Creighton University – School of Medicine, Omaha, NE

2019-present	Professor and Chair, Department of Obstetrics and Gynecology; CUSOM - Creighton University School of Medicine
2019-present	Associate Dean Women's Health
2019-present	Director, Henry Lynch Hereditary Cancer Center, expanded to the Lynch Comprehensive Cancer Research Center LCCRC); Creighton University School of Medicine

Selected Publications

1. Uehara D, **Eisner RF**. Indications for retrograde cystourethrogram in trauma. ***Ann Emerg Med,*** 15(3) 270-272, 1986.

2. Uehara D, **Eisner RF**. Indications for intravenous pyleography in trauma. ***Ann Emerg Med,*** 15(3): 266-269, 1986.

3. **Eisner RF**, et al. The efficacy of a standard seizure work-up in the emergency department. ***Ann Emerg Med,*** 15(1): 33-39, 1986.

4. **Eisner RF**, Neiberg R, Berek JS. Synchronous primary neoplasms of the female reproductive tract. *Gynecologic Oncology* 33:335-339, 1989.

5. Turnbull TL, Hoek Vanden, TL, Howes D, **Eisner RF**. Utility of laboratory studies in the emergency department patient with new-onset seizure. ***Ann Emerg Med,*** 19(4):373-377, 1990.

6. **Eisner RF**, Montz FJ, Berek JS. Cytoreductive surgery for advanced ovarian cancer: Cardiovascular evaluation with pulmonary artery catheters. ***Gynecologic Oncology***, 37:311-314, 1990.

7. **Farias-Eisner R**, Lagasse LD, Karlan BY. Diagnosis and Management of Injuries to the Genitourinary and Gastrointestinal Tracts. ***Infert Reprod Med Clin North Amer,*** 3(4)839-847, 1992.

8. **Farias-Eisner R**, Berek JS. Current Management of Invasive Squamous Carcinoma of the Vulva. ***Clinical Geriatric Medicine***, 9(1):131-143, 1993.

9. **Farias-Eisner R**, Braly P, Berek JS. Solitary Recurrent Metastasis of Epithelial Ovarian Cancer in the Spleen. ***Gynecologic Oncology***, 48:338-341, 1993.

10. Cirisano FD, Greenspoon JS, Stenson R, **Farias-Eisner R**, Karlan BY, Lagasse LD. The Etiology and Management of Diarrhea in the Gynecologic Oncology Patient. ***Gynecologic Oncology***, 50(1):45-48, 1993.

11. **Farias-Eisner R**, Sherman P, Aeberhard E, Chaudhuri G. Nitric Oxide is an Important Mediator of Tumoricidal Activity In Vivo. ***Proc Natl Acad Sci U S A***, 91, 9407-9411 September, 1994.

12. **Farias-Eisner R**, Kim YB, Berek JS. Surgical Management of Ovarian Cancer. ***Seminars in Surgical Oncology***, 10:241, 268-275, 1994.

13. **Farias-Eisner R**, Cirisano FD, Grouse D, Leuchter RS, Karlan BY, Lagasse LD, Berek JS. Conservative and Individualized Surgery in Early Stage (T1-2, N0-1, M0) Vulvar Cancer. ***Gynecologic Oncology;*** 53, 55-58, 1994.

14. **Farias-Eisner R**, Teng F, Oliveira M, Leuchter RS, Karlan BY, Lagasse LD, Berek JS. The Influence of Tumor Number Size and Distribution After Optimal (< 0.5 mm) Primary Cytoreductove Surgery for Epithelial Ovarian Cancer. ***Gynecologic Oncology***, 551, 108-110, 1994.

15. **Farias-Eisner R**, Sherman P, Aeberhard E, Chaudhuri G. Nitric Oxide is an Important Mediator of Tumoricidal Activity *In Vivo*. ***Proc Natl Acad Sci USA***, 91, 9407-9411-- September, 1994

16. Kim, YB, Menda S, YB, **Farias-Eisner R**. *Care of the Critically Ill Cancer Patient*. 123-145. In: Fowler WC, Jordon J, Lawrence WD, Shingleton H (Eds): Gynecologic Oncology: Current Diagnosis and Treatment, WB Saunders, London, 1994.

17. **Farias-Eisner R**, Casey KA, Walker DL, Shapter A, Berek JS. *Cervix, Vagina and Vulva*. 1527-1567. In: Abeloff MD, Armitage JO, Lichter HS, Nieberhurber JE (Eds): Clinical Oncology, Churchill Livingston, NY, 1995.

18. **Farias-Eisner R**, Walker DL, Berek JS, *Gynecologic Cancers*. 200-227. In: Casciato DA (Eds): Manual of Clinical Oncology, Churchill Livingston, NY, 1995.

19. Thomsen LL, Farias-Eisner R, Chaudhuri G. Nitric Oxide: role in Human Cervical Cancer. ***The Biology of Nitric Oxide*** (Part V) 298, 1996.

20. **Farias-Eisner R**; Chaudhuri G; Aeberhard E; Fukuto JM; Dysgerminoma: The Chemistry and Tumoricidal Activity of Nitric Oxide/Hydrogen Peroxide and the Implications to Cell Resistance/Susceptibility. ***Journal of Biological Chemistry***, 271(11): 6144-51. March, 1996.

21. Elkas J; **Farias-Eisner R**; Cancer of the Uterine Cervix. ***Current Opinion in Obstetrics and Gynecology***, 47-50; February, 1998.

22. **Farias-Eisner R**, Hobel CJ, The Human Genome: Application to Obstetrics and Gynecology: 44-51. Hacker N, Moore JG (Eds): *Essentials of Obstetrics and Gynecology*: 3rd Edition: WB Saunders Co.; 1998.

23. Nathan L, **Farias-Eisner R,** Endothelium-Derived Vasodepressors in Obstetrics and Gynecology. 52-56. Hacker N, Moore JG, *Essentials of Obstetrics and Gynecology*: 3rd Edition. WB Saunders Co.; 1998.

24. **Farias-Eisner R,** Hobel CJ, The Human Genome: Application to Obstetrics and Gynecology: 44-51. Hacker N, Moore JG (Eds): Essentials of Obstetrics and Gynecology: 3rd Edition: WB Saunders Co.; 1998.

25. Nathan L, **Farias-Eisner R,** Endothelium-Derived Vasodepressors in Obstetrics and Gynecology. 52-56. Hacker N, Moore JG, Essentials of Obstetrics and Gynecology: 3rd Edition. WB Saunders Co.; 1998.

26. **Farias-Eisner R,** The Molecular Mechanism(s) of Nerve Growth Factor – Driven Cellular Differentiation; PhD Thesis; Molecular Biology Institute, 1999

27. **Farias-Eisner R**, Vician L, Reddy S, Silver A, Rabbani AS, Herschman; The urokinase plasminogen activator receptor, UPAR, is preferentially induced by Nerve Growth Factor in PC12 pheochromocytoma cells and is required for NGF-driven differentiation. ***Journal of Neuroscience,*** 1; 20(1): 230-9; Jan, 2000.

28. Herschman HR, Ferguson GD, Feldman JD, **Farias-Eisner R**, Vician L; Searching for depolarization-induced genes that modulate synaptic plasticity and neurotrophin-induced genes that mediate neuronal differentiation. ***Neurochemistry Research***; 25(5):591-602; May, 2000.

29. **Farias-Eisner R**, Walker DL, Berek JS, *Gynecologic Cancers*. 200-227. In: Casciato DA (Eds): **Manual of Clinical Oncology**, Churchill Livingston, NY, 2000.

30. Vician L, **Farias-Eisner R**, Silver A, Basconcillo R, Herschman HR. NID67: a small membrane protein differentially induced by NGF versus EGF in PC12 cells. ***J. Neurosci. Research***. Apr 15; 64(2):108-20; 2001.

31. **Farias-Eisner R**, Vician L, Reddy S, Basconcillo R, Rabbani SA, Wu YY, Bradshaw RA, Herschman HR. Expression of the urokinase plasminogen activator receptor, UPAR, is transiently required during "priming" of PC12 cells in NGF-directed cellular differentiation. ***J. of Neurosci. Research***. 15; 63(4): 341-346; Feb, 2001.

32. **Farias-Eisner R**; Chaudhuri G; Nitric Oxide and Ovarian Cancer. ***Nitric Oxide***. June 2002.

33. Memarzadeh S, Kozak KR, Chang L, Natarajan S, Shintaku P, Reddy ST, **Farias-Eisner R,** Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer. ***Proc Natl Acad Sci U S A,*** 6; 99(16):10647-52, 2002.

34. Memarzadeh S, Holschneider C, Bristow R, Jones N, Fu YS, Karlan BY, Berek JS, **Farias-Eisner R**, FIGO Stage III and IV Uterine Papillary Serous Carcinoma: Impact of Residual Disease on Survival. ***Int J Gynecol Cancer*** 12(5): 454-8, 2002.

35. Memarzadeh S, Lee SB, Berek JS, **Farias-Eisner R.** CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. ***Int J Gynecol Cancer***. Mar-Apr;13(2):120-4, 2003.

36. Bagga D, Wang L, **Farias-Eisner R**, Glaspy JA, Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. ***Proc Natl Acad Sci U S A***. Feb 18; 100(4): 1751-6. Epub Feb 10, 2003.

37. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, **Farias-Eisner R**. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. ***Proc Natl Acad Sci U S A***. Oct 14;100(21):12343-8. Epub Oct 01, 2003.

38. Pakneshan P, Szyf M, **Farias-Eisner R**, Rabbani SA. Reversal of the hypomethylation status of urokinase promoter blocks breast cancer growth and metastasis. ***J Biol Chem***. Jul 23; 279(30):31735-44. Epub 2004 May 18, 2004.

39. Kozak KR, Su F, Luong MN, Luong SA, Reddy ST, **Farias-Eisner R**. Characterization of four Biomarkers for the Early Detection of Ovarian Cancer, ***Proteomics***, Nov;5(17):4589-96; 2005.

40. Su F, Kozak KR, Herschman H, Reddy ST, **Farias-Eisner R**. Characterization of the rat urokinase plasminogen activator receptor promoter in PC12 cells. ***J Neurosci Res***. Jul; 85(9):1952-8, 2007.

41. Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H, Grijalva V, Hama S, Kozak K, Buga G, Whitelegge JP, Lee TD, **Farias-Eisner R**, Navab M, Fogelman AM, Reddy ST. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. ***J Biol Chem***, Aug 10; 282(32):23698-707. Epub Jun 7, 2007.

42. Su F, Lang, J, Kozak KR, Reddy ST, **Farias-Eisner R**, Validation of Candidate Serum Ovarian Cancer Biomarkers for Early Detection, ***Biomarker Insights***, Oct 16;2:369-75, 2008.

43. Nossov V, Amneus, M , Su F, Lang J, Janco J, Reddy S; **Farias-Eisner R**, The early detection of ovarian cancer: From traditional methods to proteomics. Can we really do better than serum CA-125? ***Am J Obstet Gynecol***, Sep; 199(3):215-23. Epub May 12, 2008.

44. Nosov V, Silva I, Tavassoli F, Adamyan L, **Farias-Eisner R**, Schwartz PE, Predictors of recurrence of ovarian granulosa cell tumors. ***Int J Gynecol Cancer***. May;19(4):628-33, 2009.

45. **Farias-Eisner R**, Horblyuk R, Franklin M, Lunacsek OE, Happe LE, Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery. ***Curr Med Res Opin***. May; 25(5):1081-7, 2009**.**

46. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, Reddy S, **Farias-Eisner R**. Validation of serum biomarkers for detection of early-stage ovarian cancer. ***Am J Obstet Gynecol***. 2009 Jun; 200(6):639.e1-5. Epub Mar 14, 2009.

47. Farias-Eisner G, Su F, Robins T, Kotlerman J, Reddy S, **Farias-Eisner R**, Validation of serum biomarkers for detection of early-stage and late-stage endometrial cancer. ***Am J Obstet Gynecol***, Sep 19, 2009.

48. Imaizumi S, Grijalva V, Priceman S, Wu L, Su F, **Farias-Eisner R**, Hama S, Navab M, Fogelman AM, Reddy ST. Mitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels. ***Mol Genet Metab***. 2010 Sep; 101(1):66-75. Epub 2010 Jun 9.

49. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Navab M, Fogelman AM, Reddy ST, **Farias-Eisner R**. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. ***Proc Natl Acad Sci U S A***. 2010 Nov 16; 107(46): 19997-20002. Epub 2010 Nov 1.

50. Vasquez SX, Gao F, Su F, Grijalva V, Pope J, Bill Martin B, Stinstra J, Masner M, Shah N, Weinstein DM, Reddy ST, **Farias-Eisner R.** MicroCT Imaging and Blood Vessel Diameter Quantitation of Preclinical Mouse Specimen Vasculature with Radiopaque Silicone Polymer Injection Medium, ***PLoS One***. 2011 Apr 18; 6(4): e19099.

51. Feng Gao F, Vasquez SX, Su F, Roberts S, Shah N, Grijalva V, Imaizumi S, Chattopadhyay A, Ganapathy E, Meriwether D, Johnston B, Anantharamaiah GM, Navab M, Fogelman AM, Reddy ST, **Farias-Eisner R**, L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF / basic FGF signaling pathways, ***Integr Biol (Camb)***. 2011 Apr; 3(4): 479-89.

52. Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, Kwon M, Ganapathy E, Meriwether D, **Farias-Eisner** R, Fogelman AM, Reddy ST. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. ***Circ J.*** 2011 Jun 24; 75(7): 1533-8. Epub 2011 May 28.

53. Meriwether D, Imaizumi S, Grijalva V, Hough G, Vakili L, Anantharamaiah GM, **Farias-Eisner** R, Navab M, Fogelman AM, Reddy ST, Shechter I. Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma. ***J Lipid Res***. 2011 Oct; 52(10):1795-809.

54. Ganapathy E, Meriwether D, Su F, Grijalva V, Devarajan A, Gao F, Chattopadhyay A, Reddy ST, **Farias-Eisner R**, D-4F, an apoA-I mimetic peptide, inhibits proliferation and viability of epithelial ovarian cancer cells by upregulating the anti-oxidant enzyme MnSOD, ***Int J Cancer***. 2012 Mar 1; 130(5): 1071-81.

55. Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, Imaizumi S, Navab M, Fogelman AM, Reddy ST, **Farias-Eisner R**. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. ***Mol Cancer Ther.*** 2012 Jun; 11(6):1311-9.

56. Gao F, Chattopadhyay A, Navab M, Grijalva V, Su F, Fogelman AM, Reddy ST, **Farias-Eisner R**. Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1α in human ovarian cancer cell lines and a mouse ovarian cancer model., ***J Pharmacol Exp Ther.*** 2012 Aug; 342(2): 255-62.

57. Schweikert EM, Devarajan A, Witte I, Wilgenbus P, Amort J, Förstermann U, Shabazian A, Grijalva V, Shih DM, **Farias-Eisner R**, Teiber JF, Reddy ST, Horke S. PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. ***Cell Death Differ.*** 2012 Sep; 19(9): 1549-60.

58. Chattopadhyay A, Navab M, Hough G, Gao F, Meriwether D, Grijalva V, Springstead JR, Palgunachari MN, Namiri-Kalantari R, Su F, Van Lenten BJ, Wagner AC, Anantharamaiah GM, **Farias-Eisner R**, Reddy ST, Fogelman AM. A Novel Approach to Oral ApoA-I Mimetic Therapy. ***J Lipid Res***. 2012 Aug; 342(2): 255-62.

59. Chattopadhyay A, Navab M, Hough G, Gao F, Meriwether D, Grijalva V, Springstead JR, Palgnachari MN, Namiri-Kalantari R, Su F, Van Lenten BJ, Wagner AC, Anantharamaiah GM, **Farias-Eisner R**, Reddy ST, Fogelman AM. A novel approach to oral apoA-I mimetic therapy. ***J Lipid Res.*** 2013 Apr; 54(4): 995-1010.

60. Navab M, Hough G, Buga GM, Su F, Wagner AC, Meriwether D, Chattopadhyay A, Gao F, Grijalva V, Danciger JS, Van Lenten BJ, Org E, Lusis AJ, Pan C, Anantharamaiah GM, **Farias-Eisner R**, Smyth SS, Reddy ST, Fogelman AM. Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. ***J Lipid Res.*** 2013 Dec; 54(12):3403-18.

61. Sen S, Kawahara B, Fry NL, **Farias-Eisner R**, Zhang D, Mascharak PK, Chaudhuri G. A light-activated NO donor attenuates anchorage independent growth of cancer cells: Important role of a cross talk between NO and other reactive oxygen species. ***Arch Biochem Biophys.*** 2013 Dec;540(1-2):33-40.

62. Gao F, Liang B, Reddy ST, **Farias-Eisner R**, Su X. Role of inflammation-associated microenvironment in tumorigenesis and metastasis. ***Curr Cancer Drug Targets.*** 2014 Jan; 14(1):30-45.

63. Cohen JG, White M, Cruz A, **Farias-Eisner R**. In 2014, can we do better than CA125 in the early detection of ovarian cancer? ***World J Biol Chem***. 2014 Aug 26; 5(3): 286-300. Review.

64. Chattopadhyay A, Grijalva V, Hough G, Su F, Mukherjee P, **Farias-Eisner R**, Anantharamaiah GM, Faull KF, Hwang LH, Navab M, Fogelman AM, Reddy ST. Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer. ***Pharmacol Res Perspect***. 2015 Aug;3(4):e00154. doi: 10.1002/prp2.154. Epub 2015 Jun 24.

65. Namiri-Kalantari R, Gao F, Chattopadhyay A, Wheeler AA, Navab KD, **Farias-Eisner R**, Reddy ST. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory. ***Biofactors.*** 2015 May 6; 41(3):153-9.

66. Sen S, Kawahara B, Gupta D, Tsai R, Khachatryan M, Roy-Chowdhuri S, Bose S, Yoon A, Faull K, **Farias-Eisner R**, Chaudhuri G. Role of cystathionine β-synthase in human breast Cancer. ***Free Radic Biol Med***. 2015 Jun 4; 86:228-238.

67. Sen S, Kawahara B, Mahata SK, Tsai R, Yoon A, Hwang L, Hu-Moore K, Villanueva C, Vajihuddin A, Parameshwar P, You M, Bhaskar DL, Gomez O, Faull KF, **Farias-Eisner R**, Chaudhuri G. Cystathionine: A novel

oncometabolite in human breast cancer. ***Arch Biochem Biophys.*** 2016 Aug 15;604:95-102. doi: 10.1016/j.abb.2016.06.010. Epub 2016 Jun 14.

68. Parker W, Berek JS, Pritts E, Olive D, Kaunitz AM, Chalas E, Clarke-Pearson D, Goff B, Bristow R, Taylor HS, **Farias-Eisner R**, Fader AN, Maxwell GL, Goodwin SC, Love S, Gibbons WE, Foshag LJ, Leppert PC, Norsigian J, Nager CW, Johnson T, Guzick DS, As-Sanie S, Paulson RJ, Farquhar C, Bradley L, Scheib SA, Bilchik AJ, Rice LW, Dionne C, Jacoby A, Ascher-Walsh C, Kilpatrick SJ, Adamson GD, Siedhoff M, Israel R, Paraiso MF, Frumovitz MM, Lurain JR, Al-Hendy A, Benrubi GI, Raman SS, Kho RM, Anderson TL, Reynolds RK, DeLancey J. An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. ***J Minim Invasive Gynecol.*** 2016 Mar-Apr;23(3):303-8. doi: 10.1016/j.jmig.2015.12.012. Epub 2016 Jan 8.

69. Sen S, Kawahara B, Mahata SK, Tsai R, Yoon A, Hwang L, Hu-Moore K, Villanueva C, Vajihuddin A, Parameshwar P, You M, Bhaskar DL, Gomez O, Faull KF, **Farias-Eisner R**, Chaudhuri G. Cystathionine: A novel oncometabolite in human breast cancer. ***Arch Biochem Biophys.*** 2016 Aug 15; 604:95-102. doi: 10.1016/j.abb.2016.06.010. Epub 2016 Jun 14.

70. Ramadoss S, Sen S, Ramachandran I, Roy S, Chaudhuri G, **Farias-Eisner R**. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. ***Oncogene.*** 2017 Mar; 36(11):1537-1545. doi: 10.1038/onc.2016.320. Epub 2016 Oct 3.

71. Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim J, Nava M, Clayton S, Pietras R, **Farias-Eisner R**, Vadgama JV. A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. ***Breast Cancer Res Treat.*** 2017 Jun;163(3):449-460. doi: 10.1007/s10549-017-4211-y. Epub 2017 Mar 23

72. Liang MI, Wong DH, Walsh CS, **Farias-Eisner R**, Cohen JG. Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers. ***J Genet Couns***. 2018 Feb; 27(1):177-186. doi: 10.1007/s10897-017-0135-2. Epub 2017 Aug 7.

73. Devarajan A, Su F, Grijalva V, Yalamanchi M, Yalamanchi A, Gao F, Trost H, Nwokedi J, Farias-Eisner G, **Farias-Eisner R**, Fogelman AM, Reddy ST. Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer, ***Cell Death Dis.*** 2018 Mar 12; 9(3):392. doi: 10.1038/s41419-018-0395-2.PMID: 2953122

74. Kaufman M, Cruz A, Thompson J, Reddy S, Bansal N, Cohen JG, Wu Y, Vadgama J, **Farias-Eisner R**. A review of the effects of healthcare disparities on the experience and survival of ovarian cancer patients of

different racial and ethnic backgrounds. ***J Cancer Metastasis Treat.*** 2019; 5. pii: 13. doi: 10.20517/2394-4722.2018.25. Epub 2019 Feb 27.

75. Nava M, Dutta P, **Farias-Eisner R**, Vadgama JV, Wu Y. Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance, ***Sci Rep.*** 2019 Mar 26; 9(1):5141. doi: 10.1038/s41598-019-41672-6.PMID: 30914750.

76. Nava M, Dutta P, Zemke NR, **Farias-Eisner R**, Vadgama JV, Wu Y. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets. ***BMC Med Genomics***. 2019 Feb 8;12(1):32. doi: 10.1186/s12920-019-0477-8.

77. Su F, Spee C, Araujo E, Barron E, Wang M, Ghione C, Hinton DR, Nusinowitz S, Kannan R, Reddy ST, **Farias-Eisner R.** A Novel HDL-Mimetic Peptide HM-10/10 Protects RPE and Photoreceptors in Murine Models of Retinal Degeneration, ***Int J Mol Sci.*** 2019 Sep 27;20(19):4807.

78. Nava M, Dutta P, Zemke NR, ***Farias-Eisner R***, Vadgama JV, Wu Y. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets ***BMC Med Genomics***. 2019 8;12(1):32.

79. Su F, Anantharamaiah GM, Mayakonda N, Palgunachari C, White R, Stessman H, Wu Y, Vadgama V, Pietras R, Nguyen D, Reddy ST, **Farias-Eisner R.** Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice. ***Int J Mol Sci.*** 2020 8: 1-15.

80. Asokan Devarajan, Dawoud Sulaiman, Feng Su, Ekambaram Ganapathy, **Robin Farias-Eisne**r and Srinivasa Reddy; ***Abstract 3309***: Cardioprotective paraoxonase 2 enhances the tumoricidal activity of natural killer cells in a paracrine manner; Proceedings: ***AACR Annual Meeting*** 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA

81. Asokan Devarajan, Feng Su, Dawoud Sulaiman, Dorothy Nguyen, **Robin Farias-Eisner** and Srinivasa T. Reddy; Abstract 1472: Paraoxonase 3 is a novel tumor suppressor protein in xenograft mouse model; Proceedings: ***AACR Annual Meeting*** 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA

82. Asokan Devarajan, Victor Grijalva, Dawoud Sulaiman, Feng Su, Ellen O'C onnor, **Robin Farias-Eisner** and Srinivasa Reddy ***Abstract 3946:*** HDL associated Paraoxonase 1 reduces the ovarian tumorigenesis by enhancing the HDL function; Proceedings: ***AACR***

Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA

83. Burnett Tarasiewicz M, Strother A**, Farias-Eisner R** *et al,* Early Endometrial Cancer Treatment: A Shifting Paradigm, ***Journal of Archives of Clinical Case Studies and Case Reports*** 2021 *in press*

84. *DeAngelo C,* Burnett Tarasiewicz M, Strother A, **Farias-Eisner R** *et al*, Endometriosis and Cancer: A Malignant Molecular Profile, ***J Cancer Res Therap Oncol*** 2021 *in press*

85. Coté JJ, ***Farias-Eisner R*** *et al,* COVID-19 and a novel initiative to improve safety by 3D printing personal protective equipment parts from computed tomography, 2021 ***3D Printing in Medicine*** *In Press*

APPENDIX A

RESEARCH SUPPORT AT DGSOM AND CUSOM

ONGOING RESEARCH SUPPORT

1. **CA143930 U54 Farias-Eisner (PI – UCLA campus)**
   9/29/2009-8/31/2020
   NIH/NCI - Charles Drew/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities.
   The major goal of this project is to eliminate health disparities in a cancer cohort.
2. **Annenberg Foundation Award**
   Farias-Eisner (PI) - 6/2018-6/2021

COMPLETED RESEARCH SUPPORT

1. NIH-R03 Independent Investigator Award – 2001 – 2004
2. Liz Tilberis Ovarian Cancer Scholar Independent Investigator Award – 2001- 2006 (no cost extension)
3. Jonsson Cancer Center Independent Investigator (Stranahan) Award– 2004 – 2005
4. Department of Veteran Affairs MERIT 1 (RO1 Equivalent) Grant Award (Principal Investigator) – 2006-2012 (no cost extension)
5. 27469-22 Farias-Eisner (PI)
   4/01/1994-2019
   NIH/NCI - Gynecologic Oncology Group
   The major goal of this project is to conduct clinical trials designed for the detection, prevention and treatment of gynecologic malignancies.

APPENDIX B

PROFESSIONAL EXPERIENCE

DIRECTOR, HEREDITARY CANCER CENTER (HCC) AT CUSOM (2019-present)

- Innovative research programs of excellence supporting basic science, translational science, and clinical research programs
- Discovery of novel genetic variants for the early diagnosis of new predictors of devastating cancers and other pro-inflammatory conditions
- New drug discovery program

CHAIR, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY – CUSOM
(2019-PRESENT)

- Created Clinical, Research, and Educational Centers of Excellence
- Established subspecialty services in Gynecologic Oncology, Urogynecology and Pelvic Floor Disorders, Reproductive Endocrinology, Maternal Fetal Medicine, and Genetics
- Community engagement and development programs of excellence

MEDICAL DIRECTOR – WOMEN'S SERVICE LINE - CLINICS (2019-PRESENT)

- Created centers of clinical excellence
- Created centers of subspecialty excellence –
- Established subspecialty services in Gynecologic Oncology, Urogynecology and Pelvic Floor Disorders, Reproductive Endocrinology, Maternal Fetal Medicine, and Genetics

MEDICAL DIRECTOR – WOMEN'S SERVICE LINE - HOSPITAL (2019-PRESENT)

- Created centers of clinical excellence
- Created centers of subspecialty excellence –
- Established subspecialty services in Gynecologic Oncology, Urogynecology and Pelvic Floor Disorders, Reproductive Endocrinology, Maternal Fetal Medicine, and Genetics

DEVELOPMENT PROGRAMS – COMMUNITY ENGAGEMENT – PHILANTHROPIC PROGRAMS - DGSOM AND CUSOM

- Established Philanthropy/Development Program for the Department of Obstetrics and Gynecology, DGSOM at UCLA, and now at CUSOM.
- Expanded the level of extra-mural funding, while focusing on career development and advancement of junior, mid-level, and senior faculty in various Divisions and Departments;
- Established an effective philanthropic initiative comprised of grateful patients, for Divisions and Departments;

- Created a highly successful Capital Development Program network for the Department of Obstetrics and Gynecology, through the effective cultivation of individual donors, corporations, and foundations with a tailored approach to philanthropic giving.
- Generated an individualized, donor-centered, approach to capital development that spanned over a decade of fund-raising realizations for the department, and shaped a leadership, and pioneering role in development which significantly and positively impacted the careers of junior, intermediate, and senior faculty; the academic careers of which were mentored, nurtured, and supported through personalized targeted philanthropy.
- Planned and executed major, and yet discreet, fundraising campaigns, including major achievements with the Carl and Roberta Deutsch Foundation, the Stark Family Foundation, the Farah Fawcet Foundation, the Stand Up to Cancer Foundation, and numerous generous anonymous donors.

VICE CHAIR, ADMINISTRATION, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY – DGSOM (2005-2019)

- The Vice Chair, Administration, was created in 2005 as a new key and influential administrative position, within the Department of Obstetrics and Gynecology, and within the DGSOM, at UCLA, the Vice Chair, Administration, which required a unique skill set commensurate with that of a Department Chair, and consistently mandated an ability to function at the level of Department Chair;
- For over a decade, the administrative experience gleaned was commensurate with that gleaned from a position of Department Chair, including high level leadership skills in the areas of clinical, research, educational, development, philanthropic, budgetary, and community engagement;
- Contributed to the Department's rise to be a highly effective, and successful, administrative model;
- Provided clinical and academic perspective within the Dean's Executive Council, representing the Department of Obstetrics and Gynecology at the monthly meeting of all academic Chairs;
- Established a successful multimillion-dollar Departmental fund-raising, and development program, through a highly effective community outreach, and wide network, program;
- Established a multitude of successful strategic clinically integrated community satellite practices;
- Executed a successful strategic plan to integrate community physicians into our sustainable and robust clinical mission;
- Implemented a strategic plan to balance research and education missions with those of the academic enterprise;
- Authored and executed a successful comprehensive Departmental strategic plan to unify, and align, the University, Dean's Office, and Departmental academic missions, with that of the Health Care System Enterprise;
- Established effective recruitment and retention strategies for key faculty;

- Established an oversight and monitoring system for the Departmental Practice Plan, a 'Catalyst Fund' committee that recognized a key set of Guiding Principles for Departmental revenue, and how the funds from clinical endeavors could potentially flow ('Funds Flow') to the academic mission;
- Provided clinical and academic leadership at the Chair's meetings, as the Chair's designee, representing the Department of Obstetrics and Gynecology - academic Chairs meeting;
- Established a successful multimillion-dollar Departmental fund-raising, and development program;
- Established a lucrative strategic clinic integration model for Gynecology, and Gynecologic Oncology, health care through effective community satellite partnerships;
- Executed a successful strategic plan to clinically integrate community physicians into our sustainable and robust clinical mission;

CHIEF, DIVISION OF GYNECOLOGIC ONCOLOGY, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, AT DGSOM AT UCLA
(2005 – 2019)

- Founded a novel model for the Division of Gynecologic Oncology that permitted rapid growth, and a reputation for academic excellence.
- The Division recruited 4 FTE Faculty, all trained in the STAR (Specialty Training in Advanced Research), achieving PhD degrees in Molecular Biology, through the Molecular Biology Institute at UCLA.
- Each Faculty member of the Division established an independent research laboratory.
- The Division executed a model of intense mentorship, and career development, in preparation for leadership positions in academic medicine.
- Two of the Faculty members have subsequently been promoted to Division Director, and Associate Division Director positions, respectively at major academic institutions.
- The Division focused upon the establishment of a leadership role in numerous academic arenas; through the founding and implementation of pioneering programs in clinical, research, educational, community engagement, and development spaces.
- The Division has brought to UCLA over $10M in NIH research funding, and over $5M in private donor support; in so doing the Division of Gynecologic Oncology at UCLA emerged as a top leader, internationally, in the academic areas of clinical, research, education, community engagement, and philanthropy and development.
- Founded the Minimally Invasive Gynecologic Oncology Program comprised of the Robotic-Assisted Minimally Invasive Gynecologic Oncology Program, and the Laparoscopic-Assisted Minimally Invasive Gynecologic Oncology Program, at UCLA.
- Established a leadership role for the Robotic Surgical Gynecologic Oncology Program at UCLA immediately following FDA approval in 2006;
- Proctored, and trained, all of the Gynecology Oncology Faculty, in order to

launch the Minimally Invasive Surgical Program; preforming the first Robotic-Assisted Minimally Invasive Gynecologic Oncology major procedures, in the state of California.

- Initiated the Animal and Dry Lab Programs for Resident and Fellow Trainees, at UCLA.
- Obtained IRB approval, and industry support, in order to effectively and successfully launch a Robotic CASIT Simulation Laboratory Program and an *In vivo* Animal Laboratory, for Resident and Fellow Trainees, and Faculty.
- Founded a new model for the multidisciplinary, patient-centered Tumor Board Conference. The Tumor Board Conference emerged as a prototype in high quality multidisciplinary, patient-centered care for Gynecologic malignancies; and rapidly emerged as a model for Multidisciplinary, Multi-institution, and Multi-specialty Gynecologic Oncology care encompassing a team-driven comprehensive approach to women's cancer care, uniting the areas of Gynecologic Oncology surgery, Radiation Oncology, Medical Oncology, Pathology, Diagnostic Radiology, Oncology Nursing, Social Services, Nutrition, and Psychosocial support under one roof;
- The Division quickly assumed a leadership role nationally and internationally in the areas of clinical, research, educational, development, philanthropic, budgetary, and community engagement.
- Established a successful multimillion-dollar Divisional fund-raising, and development program;
- Established a lucrative strategic clinic integration model for Gynecologic Oncology, delivering high quality health care through effective community satellite partnerships;
- Executed a successful strategic plan to clinically integrate community physicians into our sustainable and robust clinical mission;
- Implemented an immensely strategic plan to balance research and education missions with those of the global clinical enterprise, through community philanthropic business partnerships;
- High retention and recruitment rates, 2 surgeons were recently promoted to national key academic leadership positions; both to become Division Chiefs, and Associate Division Chiefs at other major academic institutions;
- High clinical and academic productivity;
- High level of integration of Internal Medicine Specialists;
- Outstanding track record in education, with excellent placement of Resident Physician and Fellow Trainees to academic appointments at superb academic institutions;
- Recruited to new highly accomplished junior faculty members to execute a greatly successful current clinical integration model.

APPENDIX C

SERVICE - UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT, AND DIVISION HAS BEEN A PRIMARY FOCUS

- **Director, Hereditary Cancer Center – Creighton University - CUSOM**
- **Academic Chair –** Department of Obstetrics and Gynecology – CUSOM
- **Medical Director** – Women's Service Line – Hospital - CUSOM
- **Medical Director** – Women's Service Line – clinic – CUSOM
- **Medical School Admissions Committee** - CUSOM
- **Chair -** Health System Enterprise - Multidisciplinary Tumor Board Conference – Gynecologic malignancies
- **Associate Director –** Department Gynecologic Oncology Fellowship Training Program/Selection Committee
- **Director –** New UCLA/OVMC Gynecologic Oncology Fellowship Training Program/Selection Committee
- **Moderator –** Department Quality Assurance Committee - Department of Obstetrics and Gynecology
- **Moderator (rotating) -** Health System Enterprise/Department - Pre-operative Case Review Conference - Department of Obstetrics and Gynecology
- **Moderator –** Department Grand Rounds - Department of Obstetrics and Gynecology
- **Department Representative** – VA-WLA - Institutional Research - Review Board Committee (VA- west LA) – Department of Surgery
- **Department Representative -** Health System Enterprise - Operating Room Committee - Department of Obstetrics and Gynecology
- **Co-Chair -** Minimally Invasive Robotic Committee – Health System Enterprise
- **Department Representative -** Faculty Executive Committee (Elected position) - Health System Enterprise
- **Grant Review -** University JCCC Grant Review Committee
- **Associate Director –** University Women's Cancer Program for the JCCC
- **University Chair Review -** 5-year re-appointment Review Committee Chair Department of Anesthesia
- **University Chair Review -** 5-year re-appointment Review Committee Chair Department of Obstetrics and Gynecology
- **University Ph.D. Candidate Committees**
  Ph.D. candidate: Jannette Criscavage; Ph.D. candidate: Carrey Ng; Ph.D. candidate: Niyati Mehta
- **Chair - Promotion ad hoc committee for University Committee on Academic Personnel - academic year 2014-15**
  Tenure Promotion – Assistant to Associate Professor
- **Chair - Society of Gynecologic Oncology – National Membership Committee**
  Membership Committee - Chair
- **American Board of Obstetrics and Gynecology** (2005 – present)
  General Board

National Written Board Examiner and National Oral Board Examiner

- **American Board of General Surgery**
  General Board - Written Board Examiner (Contributor of written questions)
- **American Board of Emergency Medicine**
  General Board - Written Board Examiner (Contributor of written questions)

APPENDIX D

PERSONAL SCHOLARLY PRODUCTIVITY

SUMMARY SELECTED MENTORING AND TRAINING PROGRAMS DGSOM AND CUSOM

- Founded mentoring programs and training programs through the U54 NIH/NCI program, Farias-Eisner Laboratory, Gynecologic Oncology Division, Department of Obstetrics and Gynecology, and School of Medicine to mentor and train PhD students, undergraduate students, graduate students, medical students, sub-interns, resident physician trainees, fellow physician trainees, junior faculty, and intermediate faculty.
- Ph.D. Candidate(s) mentoring/training -
  Department of Medical and Molecular Pharmacology
  Department of Obstetrics and Gynecology
- U54 NIH/NCI Grant - Students, Trainees, Faculty - mentoring/training/teaching/research
- Undergraduate Students - mentoring/training/teaching/research
- Medical Students - mentoring/training/teaching/research
- Sub-I Program - Gynecology and Gynecologic Oncology Rotations - mentoring/training/teaching/research
- Resident Physician Trainees - mentoring/training/teaching/research
- Fellow Physician Trainees - mentoring/training/teaching/research
- Junior Faculty (Clinical and FTE) - mentoring/training/teaching/research
- Intermediate Faculty (Clinical and FTE) – mentoring/training/teaching/research
- Senior Faculty (Clinical and FTE) - mentoring/training/teaching/research

APPENDIX E

ACADEMIC IMPACT - LEADERSHIP AT DGSOM AND CUSOM

HIGHLIGHTS - LEADERSHIP EXPERIENCE AT DGSOM AND CUSOM

- Leadership experience in complex academic healthcare system enterprise and center at the Departmental, School of Medicine, University, and Institutional level
- A track record of successful community engagement and development
- A track record for establishing sustainable and effective nurturing and mentoring programs
- A strong track record for successful team-driven approaches to leadership
- A solid track record in the dedication to improve the health of the community
- A robust track record in the training of the next generation of medical students, resident trainees, fellow trainees, and faculty
- A strong track record in advancing the science of women's health and maternal and fetal outcomes through the development of successful programs in the clinical, research, educational, and community development arenas
- An enduring track record to creating strong programs in Quality Assurance, Morbidity and Mortality, and Quality Improvement, patient safety, and high-quality care
- A durable track record at the successful retention and recruitment of faculty and staff of the highest skill level to serve a highly complex healthcare system enterprise general and subspecialty Obstetrics and Gynecology practice
- A sustainable track record at effective mentoring of current faculty to set a successful trajectory for their careers.
- An enduring track record of a strong commitment to collegiality, diplomacy, diversity, fairness, high integrity and character at the Department, School of Medicine, and University level and promoting the ethos of the Institution
- A very strong track record of building upon an already existing solid clinical, research, and educational reputation and expertise
- A strong track record at the establishment of robust and sustainable business, entrepreneurial, and administrative teams
- A track record of National and International preeminence

APPENDIX F

ENTREPRENEURIAL BUSINESS-DRIVEN PROJECTS AT DGSOM AND CUSOM

- The Department academic programs that we established, at DGSOM, at UCLA, for the Department of Obstetrics and Gynecology, and for the School of Medicine, included a variety of highly successful entrepreneurial business-driven projects.
- For example, discoveries at the research bench in the Farias-Eisner Laboratory (e.g. Center for Biomarker Discovery, and Women's Cancer Research) lead to valued intellectual property for the University, in which MIA/OVA-1, a highly effective marker for ovarian cancer, commercialized by Quest Laboratories, was identified, characterized, validated, and commercialized in partnership with the University.
- The assay is used worldwide. This novel and highly accurate diagnostic platform effectively differentiate a benign from malignant ovarian mass and can be utilized to assist the primary care physician in deciding whether to refer the patient to a Gynecologic Oncologist.
- Currently, I am on a similar trajectory at CUSOM to identify novel genetic variants that are predictive of a variety of devastating pro-inflammatory diseases (e.g. cancer, endometriosis, macular degeneration).

INSTILLING A SPIRIT OF INNOVATION AT DGSOM AND CUSOM

- I believe that a sincere spirit of innovation, adventure, commitment and dedication is critical to catapult business-driven academic HealthCare to international preeminence.
- I genuinely believe that our Department and Medical School's academic success, at DGSOM and now at CUSOM, has been linked to the positive execution of an innovative and sustainable academic mission: establishing the Department, and the School of Medicine, at DGSOM and now at CUSOM, as a national and international leader of academic excellence in Women's Health, with the creation of centers of excellence in clinical, research, education, and community engagement.
- At both DGSOM and now at CUSOM, our intrepid spirit of academic adventure will create an integrated Health Care System founded with high academic distinction.

APPENDIX G

OVERALL ACADEMIC GOAL AND ACCOMPLISHMENTS AT CUSOM AND DGSOM

Robust and sustainable academic programs through the creation of excellence at the clinical, research, and educational levels.

SPECIFIC GOAL 1

CREATED CLINICAL EXCELLENCE THROUGH THE ESTABLISHMENT OF SUBSPECIALTY SERVICES AND CENTERS OF EXCELLENCE AT DAVID GEFFEN SCHOOL OF MEDICINE AT DGSOM AND CUSOM

- One of the most important goals for the Departments of Obstetrics and Gynecology was the development of an academic Clinical Service by establishing and expanding high quality subspecialty care.
- This priority in subspecialty care has been focused on the development of subspecialty care in the following five areas: 1) Gynecologic Oncology; 2) Urogynecology, Pelvic Floor, and Female Reconstructive Surgery; 3) Maternal Fetal Medicine; 4) Menopause; and 5) Female Sexual Function.
- ***Gynecologic Oncology*** – the Gynecologic Oncology service has been a flourishing subspecialty. A multidisciplinary, patient-centered, and value-based Gynecologic Oncology Center of Excellence has been established. The Medical Oncology and Radiation Oncology services, Pathology service, Genetic Counselor team, and Supportive services have worked together to implement the strategic initiative. A multidisciplinary Tumor Board Conference has been established.
- ***Urogynecology, Pelvic Floor, and Female Reconstructive Surgery*** – A Pelvic Floor Center of Excellence initiative has been a successful collaborative initiative between the Departments of Urology and Obstetrics and Gynecology, Physical Therapy, Psychiatry, and the GI services.
- ***Maternal Fetal Medicine*** - A MFM recruitment initiative has been successful and a multidisciplinary, patient-centered, and value-based Gynecologic Oncology Center of Excellence has been established.
- ***REI, Menopause*** and ***Female Sexual Functionality*** – Center of Excellence.

SPECIFIC GOAL 2

ESTABLISHED OF AN ENDURING RESEARCH/EDUCATION PROGRAM FOR THE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY AT CUSOM AND DGSOM HAS BEEN KEY TO ACHIEVING ACADEMIC EXCELLENCE

- Research/Education Teams were established comprised of a Core Faculty and Learner (Medical Student, Undergraduate Creighton University Student) anchor. A Biostatistician, and/or Technician supports the team.

- These Research Teams are comprised of a specific Faculty member and a Learner: Medical Student, Resident Trainee, or an Undergraduate Student Learner (CURAS, CIPER, Gap year, or Masters Medical Science Programs).
- We have engaged the Core Faculty and specific Supportive Contributing and interested CHI Faculty members, and have engaged Student Learners (Medical Student or Undergraduate Student).
- The successful projects: 1) Quality Improvement, 2) Sequencing Exomes to identify genetic variants as predictors of disease and/or putative novel targets for therapy, 3) novel Drug Discovery, and 4) Investigator-Initiated Clinical Pilot Trials. Publications have resulted in the areas of Basic Science/Translational, Clinical article, and Basic Science/Translational arenas.

SPECIFIC GOAL 3

COMMUNITY OUTREACH AND IDENTIFICATION OF POTENTIAL PHILANTHROPIC SUPPORT HAS BEEN CRITICAL FOR THE SUCCESS AT DGSOM OF THE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY'S RESEARCH MISSION AND NOW FOR CUSOM AND THE HEREDITARY CANCER CENTER

- The Research Mission of the Department of Obstetrics and Gynecology for CUSOM and DGSOM, and that of the Hereditary Cancer Center at CUSOM are in close alignment.
- The focus on academic excellence and the resulting academic success for the Department of Obstetrics and Gynecology at CUSOM and DGSOM has been the establishment of high-quality subspecialty care for the Department, and raising critical funds to support the ambitious Research and Educational initiatives planned.
- These Development endeavors have focused on selective community engagement, and have aligned with the Mission for the HCC.
- The surrogate endpoint has been a robust and sustainable Academic Program through the creation of excellence at the Clinical, Research, and Educational and Community Engagement levels.

APPENDIX H

LEADERSHIP AT DGSOM AND CUSOM

- Professor and Chair
  Department of Obstetrics and Gynecology at Creighton University
  School of Medicine (CUSOM)
- Associate Dean Women's Health at the CUSOM
- Director, Hereditary Cancer Center at the CUSOM
- Charles F. and Mary C. Heider Endowed Chair in Cancer Research - Creighton University
- Professor Emeritus – life-long appointment (Step VII – academic series)
- Distinguished Research Professor
- Professor and Vice Chair, Administration, Department of Obstetrics and Gynecology, at the David Geffen School of Medicine, at UCLA;
- Chief, Gynecologic Oncology in the Department of Obstetrics and Gynecology, at the David Geffen School of Medicine, at UCLA;
- Director, Center for Biomarker Discovery and Women's Cancer Research, at UCLA;
- Principal Investigator, NIH/NCI U54 Award, a program project grant to Eliminate Health Care Disparities in a Cancer Cohort;
- Principal Investigator, National Research Group (NRG), at UCLA, a national multicenter research consortium;
- Program Director for the Gynecologic Oncology Fellowship Training Program;
- National Board Examiner for several board subspecialties: Obstetrics and Gynecology, Gynecologic Oncology, General Surgery, Emergency Medicine;
- Of note, full Professor, Academic Series, Step VII – attaining Step VI status requires a rigorous review process and a designation, "international notoriety"

TRACK RECORD AT DGSOM AND CUSOM

- unique training as a Surgeon-Scientist-Educator (e.g. Professor Researcher-Educator, Molecular Biologist, Critical Care Medicine and Emergency Medicine subspecialist, Obstetrics and Gynecology, and Gynecologic Oncologist);
- A greater than 20-year experience as an Administrator (e.g. National Board Examiner; PI NIH/NCI U54 program; PI National Research Group; Department of Obstetrics and Gynecology, Vice Chair, Administration, Chief, Gynecologic Oncology);
- Trained in Emergency Medicine and Critical Care, Obstetrics and Gynecology, Gynecologic Oncology, Molecular Biology, directed a productive and innovative Molecular Biology Laboratory for 2 decades.

LEADERSHIP QUALITIES AT DGSOM AND CUSOM

- Quality leadership, visibility, and excellence at all academic levels.

- Mentorship of students, residents, fellows, junior faculty, intermediate faculty, and senior faculty, alike.
- Management skills targeting all academic faculty, voluntary physician staff, medical support staff, and ancillary personnel, alike.
- Skills in financial and business affairs.
- Skills in Quality Assurance (QA), Risk Management (RM), monitoring volume, clinical quality, clinical improvement, operations improvements and fiscal performance.
- Exemplifying a high standard of collegiality, cooperation, and communication among faculty and staff, alike.
- Promoting, creating, and sustaining excellence and integrity in clinical, research, educational, and community engagement practices.
- Creating inclusivity and a positive academic environment that fosters intra- and inter-departmental collaboration, in order to facilitate the retention and expansion of faculty, and the creation new academic programs.
- Establishing a robust and sustainable model that will deliver the highest possible quality of patient care, while concurrently expanding the clinical enterprise.
- act as a dynamic steward of the enterprise, and to engage faculty and staff, alike, in a way that all voices are included and brings forth the very best from everyone, in a manner of inclusivity, and never exclusivity.
- An advocate of human diversity and inclusivity that will promote a team-driven approach to enterprise success.
- A proponent of humility, patience, wisdom, maturity, and yet a security in one's abilities to provide substantively to the enterprise through academic value-based leadership.
- Promote an environment that respects and provides the highest integrity, character, ethical behavior, and exemplary business standards,
- Deliver strategic leadership, direction, coordination, envisioning strategy, inclusivity, building trust, transparency, and communication, strategic and visionary leadership, matrixed leadership, consensus building, collaboration, engaging people, and executing to achieve results for all academic programs of excellence in the clinical, research, educational, and community engagement environments.

LEADERSHIP MANTRA AT DGSOM AND CUSOM

- Creating a working relationship collaboratively with medical and administrative leadership to meet and exceed enterprise goals, creating and maintaining positive interactions, collegial relationships with all other Chairs, Chiefs, and Medical Directors, and developing already existing and outstanding and collaborative

faculty teams.

- Accepting with graciousness and eagerness the inherent responsibility and accountability that accompanies all facets of the department, including the clinical and academic performance of all divisions.
- Embracing with vigor the proactive advocacy for patient safety, continuous performance, Quality Assurance (QA), Quality Improvement (QI), Risk Management (RM), and efficient resource utilization.
- Advocating for the application and practice of evidence-based medicine.
- Grasping immediately and effectively and responsibly the strategic and fiscal oversight for all academic programs and initiatives.
- Executing leadership that implements the mission and vision of the Healthcare enterprise for academic excellence and scholarly activity.
- Promoting innovation and creativity in clinical, research, educational, and community engagement excellence through trust, integrity, transparency, diversity, and communication, inside and outside the department of Obstetrics and Gynecology.
- Promoting innovative and strategic operational leadership for the department in collaboration with medical center leadership.

APPENDIX I

RESEARCH SUPPORT AT DGSOM AND CUSOM

ONGOING RESEARCH SUPPORT

1. **27469-22 Farias-Eisner (PI)**
   4/01/1994-2019
   NIH/NCI - Gynecologic Oncology Group
   The major goal of this project is to conduct clinical trials designed for the detection, prevention and treatment of gynecologic malignancies.
2. **CA143930 U54 Farias-Eisner (PI – UCLA campus)**
   9/29/2009-8/31/2020
   NIH/NCI - Charles Drew/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities.
   The major goal of this project is to eliminate health disparities in a cancer cohort.
3. **Annenberg Foundation Award**
   Farias-Eisner (PI) - 6/2018-6/2021

COMPLETED RESEARCH SUPPORT

1. NIH-R03 Independent Investigator Award – 2001 – 2004
2. Liz Tilberis Ovarian Cancer Scholar Independent Investigator Award – 2001- 2006 (no cost extension)
3. Jonsson Cancer Center Independent Investigator (Stranahan) Award– 2004 – 2005
4. Department of Veteran Affairs MERIT 1 (RO1 Equivalent) Grant Award (Principal Investigator) – 2006-2012 (no cost extension)

APPENDIX J

PROFESSIONAL EXPERIENCE

DIRECTOR, HEREDITARY CANCER CENTER (HCC) AT CUSOM
(2019-present)

- Innovative research programs of excellence supporting basic science, translational science, and clinical research programs
- Discovery of novel genetic variants for the early diagnosis of new predictors of devastating cancers and other pro-inflammatory conditions
- New drug discovery program

CHAIR, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY – CUSOM
(2019-PRESENT**)**

- Created Clinical, Research, and Educational Centers of Excellence
- Established subspecialty services in Gynecologic Oncology, Urogynecology and Pelvic Floor Disorders, Reproductive Endocrinology, Maternal Fetal Medicine, and Genetics
- Community engagement and development programs of excellence

MEDICAL DIRECTOR – WOMEN'S SERVICE LINE - CLINICS
(2019-PRESENT)

- Created centers of clinical excellence
- Created centers of subspecialty excellence –
- Established subspecialty services in Gynecologic Oncology, Urogynecology and Pelvic Floor Disorders, Reproductive Endocrinology, Maternal Fetal Medicine, and Genetics

MEDICAL DIRECTOR – WOMEN'S SERVICE LINE - HOSPITAL
(2019-PRESENT)

- Created centers of clinical excellence
- Created centers of subspecialty excellence –
- Established subspecialty services in Gynecologic Oncology, Urogynecology and Pelvic Floor Disorders, Reproductive Endocrinology, Maternal Fetal Medicine, and Genetics

DEVELOPMENT PROGRAMS – COMMUNITY ENGAGEMENT – PHILANTHROPIC PROGRAMS - DGSOM AND CUSOM

- Established Philanthropy/Development Program for the Department of Obstetrics and Gynecology, DGSOM at UCLA, and now at CUSOM.
- Expanded the level of extra-mural funding, while focusing on career development and advancement of junior, mid-level, and senior faculty in various Divisions and Departments;
- Established an effective philanthropic initiative comprised of grateful patients, for Divisions and Departments;

- Created a highly successful Capital Development Program network for the Department of Obstetrics and Gynecology, through the effective cultivation of individual donors, corporations, and foundations with a tailored approach to philanthropic giving.
- Generated an individualized, donor-centered, approach to capital development that spanned over a decade of fund-raising realizations for the department, and shaped a leadership, and pioneering role in development which significantly and positively impacted the careers of junior, intermediate, and senior faculty; the academic careers of which were mentored, nurtured, and supported through personalized targeted philanthropy.
- Planned and executed major, and yet discreet, fundraising campaigns, including major achievements with the Carl and Roberta Deutsch Foundation, the Stark Family Foundation, the Farah Fawcet Foundation, the Stand Up to Cancer Foundation, and numerous generous anonymous donors.

VICE CHAIR, ADMINISTRATION, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY – DGSOM (2005-2019)

- The Vice Chair, Administration, was created in 2005 as a new key and influential administrative position, within the Department of Obstetrics and Gynecology, and within the DGSOM, at UCLA, the Vice Chair, Administration, which required a unique skill set commensurate with that of a Department Chair, and consistently mandated an ability to function at the level of Department Chair;
- For over a decade, the administrative experience gleaned was commensurate with that gleaned from a position of Department Chair, including high level leadership skills in the areas of clinical, research, educational, development, philanthropic, budgetary, and community engagement;
- Contributed to the Department's rise to be a highly effective, and successful, administrative model;
- Provided clinical and academic perspective within the Dean's Executive Council, representing the Department of Obstetrics and Gynecology at the monthly meeting of all academic Chairs;
- Established a successful multimillion-dollar Departmental fund-raising, and development program, through a highly effective community outreach, and wide network, program;
- Established a multitude of successful strategic clinically integrated community satellite practices;
- Executed a successful strategic plan to integrate community physicians into our sustainable and robust clinical mission;
- Implemented a strategic plan to balance research and education missions with those of the academic enterprise;
- Authored and executed a successful comprehensive Departmental strategic plan to unify, and align, the University, Dean's Office, and Departmental academic missions, with that of the Health Care System Enterprise;
- Established effective recruitment and retention strategies for key faculty;

- Established an oversight and monitoring system for the Departmental Practice Plan, a 'Catalyst Fund' committee that recognized a key set of Guiding Principles for Departmental revenue, and how the funds from clinical endeavors could potentially flow ('Funds Flow') to the academic mission;
- Provided clinical and academic leadership at the Chair's meetings, as the Chair's designee, representing the Department of Obstetrics and Gynecology - academic Chairs meeting;
- Established a successful multimillion-dollar Departmental fund-raising, and development program;
- Established a lucrative strategic clinic integration model for Gynecology, and Gynecologic Oncology, health care through effective community satellite partnerships;
- Executed a successful strategic plan to clinically integrate community physicians into our sustainable and robust clinical mission;

CHIEF, DIVISION OF GYNECOLOGIC ONCOLOGY, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, AT DGSOM AT UCLA
(2005–2019)

- Founded a novel model for the Division of Gynecologic Oncology that permitted rapid growth, and a reputation for academic excellence.
- The Division recruited 4 FTE Faculty, all trained in the STAR (Specialty Training in Advanced Research), achieving PhD degrees in Molecular Biology, through the Molecular Biology Institute at UCLA.
- Each Faculty member of the Division established an independent research laboratory.
- The Division executed a model of intense mentorship, and career development, in preparation for leadership positions in academic medicine.
- Two of the Faculty members have subsequently been promoted to Division Director, and Associate Division Director positions, respectively at major academic institutions.
- The Division focused upon the establishment of a leadership role in numerous academic arenas; through the founding and implementation of pioneering programs in clinical, research, educational, community engagement, and development spaces.
- The Division has brought to UCLA over $10M in NIH research funding, and over $5M in private donor support; in so doing the Division of Gynecologic Oncology at UCLA emerged as a top leader, internationally, in the academic areas of clinical, research, education, community engagement, and philanthropy and development.
- Founded the Minimally Invasive Gynecologic Oncology Program comprised of the Robotic-Assisted Minimally Invasive Gynecologic Oncology Program, and the Laparoscopic-Assisted Minimally Invasive Gynecologic Oncology Program, at UCLA.
- Established a leadership role for the Robotic Surgical Gynecologic Oncology Program at UCLA immediately following FDA approval in 2006;
- Proctored, and trained, all of the Gynecology Oncology Faculty, in order to

launch the Minimally Invasive Surgical Program; preforming the first Robotic-Assisted Minimally Invasive Gynecologic Oncology major procedures, in the state of California.

- Initiated the Animal and Dry Lab Programs for Resident and Fellow Trainees, at UCLA.
- Obtained IRB approval, and industry support, in order to effectively and successfully launch a Robotic CASIT Simulation Laboratory Program and an *In vivo* Animal Laboratory, for Resident and Fellow Trainees, and Faculty.
- Founded a new model for the multidisciplinary, patient-centered Tumor Board Conference. The Tumor Board Conference emerged as a prototype in high quality multidisciplinary, patient-centered care for Gynecologic malignancies; and rapidly emerged as a model for Multidisciplinary, Multi-institution, and Multi-specialty Gynecologic Oncology care encompassing a team-driven comprehensive approach to women's cancer care, uniting the areas of Gynecologic Oncology surgery, Radiation Oncology, Medical Oncology, Pathology, Diagnostic Radiology, Oncology Nursing, Social Services, Nutrition, and Psychosocial support under one roof;
- The Division quickly assumed a leadership role nationally and internationally in the areas of clinical, research, educational, development, philanthropic, budgetary, and community engagement.
- Established a successful multimillion-dollar Divisional fund-raising, and development program;
- Established a lucrative strategic clinic integration model for Gynecologic Oncology, delivering high quality health care through effective community satellite partnerships;
- Executed a successful strategic plan to clinically integrate community physicians into our sustainable and robust clinical mission;
- Implemented an immensely strategic plan to balance research and education missions with those of the global clinical enterprise, through community philanthropic business partnerships;
- High retention and recruitment rates, 2 surgeons were recently promoted to national key academic leadership positions; both to become Division Chiefs, and Associate Division Chiefs at other major academic institutions;
- High clinical and academic productivity;
- High level of integration of Internal Medicine Specialists;
- Outstanding track record in education, with excellent placement of Resident Physician and Fellow Trainees to academic appointments at superb academic institutions;
- Recruited to new highly accomplished junior faculty members to execute a greatly successful current clinical integration model.

SERVICE TO THE UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT, AND DIVISION HAS BEEN A PRIMARY FOCUS

- **Director, Hereditary Cancer Center – Creighton University - CUSOM**
- **Academic Chair –** Department of Obstetrics and Gynecology – CUSOM
- **Medical Director** – Women's Service Line – Hospital - CUSOM

- **Medical Director** – Women's Service Line – Clinic – CUSOM

- **Medical School Admissions Committee** - CUSOM
- **Chair -** Health System Enterprise - Multidisciplinary Tumor Board Conference – Gynecologic malignancies
- **Associate Director –** Department Gynecologic Oncology Fellowship Training Program/Selection Committee
- **Director –** New UCLA/OVMC Gynecologic Oncology Fellowship Training Program/Selection Committee
- **Moderator –** Department Quality Assurance Committee - Department of Obstetrics and Gynecology
- **Moderator (rotating) -** Health System Enterprise/Department - Pre-operative Case Review Conference - Department of Obstetrics and Gynecology
- **Moderator –** Department Grand Rounds - Department of Obstetrics and Gynecology
- **Department Representative** – VA-WLA - Institutional Research - Review Board Committee (VA- west LA) – Department of Surgery
- **Department Representative -** Health System Enterprise - Operating Room Committee - Department of Obstetrics and Gynecology
- **Co-Chair -** Minimally Invasive Robotic Committee – Health System Enterprise
- **Department Representative -** Faculty Executive Committee (Elected position) - Health System Enterprise
- **Grant Review -** University JCCC Grant Review Committee
- **Associate Director –** University Women's Cancer Program for the JCCC
- **University Chair Review -** 5-year re-appointment Review Committee Chair Department of Anesthesia
- **University Chair Review -** 5-year re-appointment Review Committee Chair Department of Obstetrics and Gynecology
- **University Ph.D. Candidate Committees**
  Ph.D. candidate: Jannette Criscavage; Ph.D. candidate: Carrey Ng; Ph.D. candidate: Niyati Mehta
- **Chair - Promotion ad hoc committee for University Committee on Academic Personnel - academic year 2014-15**
  Tenure Promotion – Assistant to Associate Professor
- **Chair - Society of Gynecologic Oncology – National Membership Committee**
  Membership Committee - Chair
- **American Board of Obstetrics and Gynecology** (2005 – present)
  General Board
  National Written Board Examiner and National Oral Board Examiner
- **American Board of General Surgery**
  General Board - Written Board Examiner (Contributor of written questions)
- **American Board of Emergency Medicine**
  General Board - Written Board Examiner (Contributor of written questions)

APPENDIX K

PERSONAL SCHOLARLY PRODUCTIVITY

SUMMARY SELECTED MENTORING AND TRAINING PROGRAMS DGSOM AND CUSOM

- Founded mentoring programs and training programs through the U54 NIH/NCI program, Farias-Eisner Laboratory, Gynecologic Oncology Division, Department of Obstetrics and Gynecology, and School of Medicine to mentor and train PhD students, undergraduate students, graduate students, medical students, sub-interns, resident physician trainees, fellow physician trainees, junior faculty, and intermediate faculty.
- Ph.D. Candidate(s) mentoring/training -
  Department of Medical and Molecular Pharmacology
  Department of Obstetrics and Gynecology
- U54 NIH/NCI Grant - Students, Trainees, Faculty - mentoring/training/teaching/research
- Undergraduate Students - mentoring/training/teaching/research
- Medical Students - mentoring/training/teaching/research
- Sub-I Program - Gynecology and Gynecologic Oncology Rotations - mentoring/training/teaching/research
- Resident Physician Trainees - mentoring/training/teaching/research
- Fellow Physician Trainees - mentoring/training/teaching/research
- Junior Faculty (Clinical and FTE) - mentoring/training/teaching/research
- Intermediate Faculty (Clinical and FTE) – mentoring/training/teaching/research
- Senior Faculty (Clinical and FTE) - mentoring/training/teaching/research

APPENDIX L

CURRENT RESEARCH – DGSOM AND CUSOM

- A growing body of literature supports the role of apolipoproteins present in HDL in the treatment of pro-inflammatory diseases including cancer.
- We examined whether three dual-domain peptides, namely AEM-28 and its analog AEM-28-2, and HM-10/10, affect tumor growth and development in mouse models of ovarian and colon cancer.
- Our studies suggest that therapeutics based on apolipoproteins present in HDL represent new and novel agents for the treatment of epithelial adenocarcinomas of the ovary and colon.
- We also studied the efficacy of HM-10/10 against other pro-inflammatory diseases, such as Age-related Macular Degeneration (AMD), which is a leading cause of blindness in the developed world. The retinal pigment epithelium (RPE) is a critical site of pathology in AMD.
- Our results demonstrated that HM-10/10 protects and rescues RPE and retina from oxidant injury and can serve as a potential therapeutic agent for the treatment of retinal degeneration.

The Farias-Eisner Laboratory was the first to report that chimera mimetic peptides (e.g. apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides, and the apoA-1/apoE and apoE/apoJ chimera mimetic peptides - HM-10/10), based on apolipoproteins present in HDL, represent novel therapeutics for the treatment of devastating epithelial adenocarcinomas (e.g. ovary and colon)

- We examined whether bovine HDL (bHDL) and three dual-domain peptides, namely AEM-28 and its analog AEM-28-2, and HM-10/10, affect tumor growth and development in mouse models of ovarian and colon cancer.
- We demonstrate that bHDL inhibits mouse colorectal cancer cell line CT26-mediated lung tumor development, and mouse ovarian cancer cell line ID8-mediated tumor burden.
- We also demonstrate that, although to different degrees, dual-domain peptides inhibit cell viability of mouse and human ovarian and colon cancer cell lines, but not that of normal human colonic epithelial cells or NIH3T3 mouse fibroblasts.
- **Our studies suggest that therapeutics based on apolipoproteins present in HDL are novel agents for the treatment of epithelial adenocarcinomas of the ovary and colon.**
  (Su F, Anantharamaiah GM, Mayakonda N, Palgunachari C, White R, Stessman H, Wu Y, Vadgama V, Pietras R, Nguyen D, Reddy ST, Farias-Eisner R**.** Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice. J Cancer Res Therap Oncol 2020 8: 1-15. ***in press)***

The Farias-Eisner Laboratory was the first to report that chimera mimetic peptides (e.g. apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides, and the apoA-1/apoE and apoE/apoJ chimera mimetic peptides - HM-10/10), based on apolipoproteins present in HDL, represent novel therapeutics for the treatment of devastating pro-inflammatory diseases (e.g. age-related macular degeneration).

- We also studied the efficacy of HM-10/10 against other pro-inflammatory diseases, such as Age-related Macular Degeneration (AMD), which is a leading cause of blindness in the developed world.
- The retinal pigment epithelium (RPE) is a critical site of pathology in AMD. Oxidative stress plays a key role in the development of AMD. We generated a chimeric high-density lipoprotein (HDL), mimetic peptide named HM-10/10, with anti-oxidant properties and investigated its potential for the treatment of retinal disease using cell culture and animal models of RPE and photoreceptor (PR) degeneration.
- **Our results demonstrate that HM-10/10 protects and rescues RPE and retina from oxidant injury and can serve as a potential therapeutic agent for the treatment of retinal degeneration.**
  (Su F, Spee C, Araujo E, Barron E, Wang M, Ghione C, Hinton DR, Nusinowitz S, Kannan R, Reddy ST, **Farias-Eisner R.** A Novel HDL-Mimetic Peptide HM-10/10 Protects RPE and Photoreceptors in Murine Models of Retinal Degeneration, ***Int J Mol Sci***. 2019 Sep 27;20(19):4807. doi: 10.3390/ijms20194807.PMID: 31569695.)

OUR EARLY RESEARCH - DGSOM

- Our team of researchers identified a group of proteins that serve as early identifiers of ovarian cancer prior to the appearance of disease on standard imaging modalities (e.g. US, MRI, PET/CT scan).
- The research led to the development of a Multivariate Index Assay (MIA/OVA1 plus), a blood test that is currently being used worldwide to distinguish between benign from malignant ovarian neoplasia.
- Building on this work, we developed HM-10/10.

- **The Farias-Eisner Laboratory was the first to report the identification of differentially expressed full-length proteins, as biomarkers, for the early detection of ovarian cancer, with high efficacy, using strong anion-exchange ProteinChips; for the potential use in diagnosis and prognosis.** Briefly, one hundred eighty-four serum samples from patients with ovarian cancer (n = 109), patients with benign tumors (n = 19), and healthy donors (n = 56) were analyzed on strong anion-exchange surfaces using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry technology. Univariate and multivariate statistical analyses applied to protein-profiling data obtained from 140 training serum samples identified three biomarker protein panels.
- When used together, these biomarker protein panels effectively distinguished serum samples from healthy controls and patients with

either benign or malignant ovarian neoplasia, with high sensitivity, specificity and accuracy. **Over the past decade, my Laboratory has focused on the identification, characterization, and validation of differentially expressed proteins that serve as biomarkers of early stage ovarian cancer.**

- **We developed an effective panel of biomarkers for the early detection of ovarian cancer, which was FDA approved for clinic use in 9/2009.**
- **We were issued the US and European Patent for this Intellectual Property in 2009, and Quest Laboratories has licensed the use of these markers form UCLA and is marketing the commercial product, Multivariate Index Assay (OVA1/MIA).**
  (Su F, Lang, J, Kozak KR, Reddy ST, **Farias-Eisner R**, Validation of Candidate Serum Ovarian Cancer Biomarkers for Early Detection, ***Biomarker Insights***, Oct 16; 2:369-75, 2008. PMCID: PMC2717832)
  (Nossov V, Amneus, M , Su F, Lang J, Janco J, Reddy S; **Farias-Eisner R**, The early detection of ovarian cancer: From traditional methods to proteomics. Can we really do better than serum CA-125? ***Am J Obstet Gynecol***, Sep; 199(3): 215-23. Epub May 12, 2008. PMID: 18468571)
  (Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, Reddy S, **Farias-Eisner R**. Validation of serum biomarkers for detection of early-stage ovarian cancer. ***Am J Obstet Gynecol***. 2009 Jun; 200(6): 639.e1-5. Epub Mar 14, 2009. PMID: 19285648)
- **The Farias-Eisner Laboratory was the first to report the characterization of four highly accurate biomarkers, representing a family of similar full length proteins, for the early detection of ovarian cancer; we had previously reported the identification of three ovarian cancer biomarker panels comprised of SELDI-TOF-MS peaks representing 14 differentially expressed full length serum proteins for the diagnosis of ovarian cancer**. Briefly, using micro-LC-MS/MS, we identified five m/z peaks as transthyretin (TTR 13.9 kDa, TTR fragment 12.9 kDa), beta-hemoglobin (Hb, 15.9 kDa), apolipoprotein AI (ApoAI, 28 kDa) and transferrin (TF, 79 kDa).
- Western and/or ELISA methods confirmed the differential expression of TTR, Hb, and TF, and multivariate analyses resulted in significant improved in the detection of early stage ovarian tumors (low malignant potential and malignant; receiver operating characteristic) as compared to cancer antigen CA125 alone. We conclude that TTR, Hb, ApoAI and TF, when combined with CA125 significantly improved the detection of early stage ovarian cancer.
- **Over the past decade, my Laboratory has focused on the identification, characterization, and validation of differentially expressed proteins that serve as biomarkers of early stage ovarian cancer.**

(Memarzadeh S, Holschneider C, Bristow R, Jones N, Fu YS, Karlan BY, Berek JS, **Farias-Eisner R**, FIGO Stage III and IV Uterine Papillary Serous Carcinoma: Impact of Residual Disease on Survival. ***Int J Gynecol Cancer*** 12(5): 454-8, 2002.)
(Memarzadeh S, Lee SB, Berek JS, **Farias-Eisner R.** CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. ***Int J Gynecol Cancer***. Mar-Apr;13(2):120-4, 2003.)
(Farias-Eisner G, Su F, Robins T, Kotlerman J, Reddy S, **Farias-Eisner R**, Validation of serum biomarkers for detection of early-stage and late-stage endometrial cancer. ***Am J Obstet Gynecol,*** Sep 19, 2009. PMID: 19766980)

The Farias-Eisner Laboratory was the first to report that Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides, and the apoA-1/apoE (AEM-2) and apoE/apoJ (HM-10/10) chimera mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.

- Briefly, we examined whether reduced levels of Apolipoprotein A-I (apoA-I) in ovarian cancer patients are causal in ovarian cancer in a mouse model. Mice expressing a human apoA-I transgene had (i) increased survival ($P < 0.0001$) and (ii) decreased tumor development ($P < 0.01$), when compared with littermates, following injection of mouse ovarian epithelial papillary serous adenocarcinoma cells (ID-8 cells).
- Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides, and the apoA-1/apoE and apoE/apoJ chimera mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.
- ApoA-I mimetic peptides reduced viability and proliferation of ID8 cells and cis-platinum-resistant human ovarian cancer cells, and decreased ID-8 cell-mediated tumor burden in C57BL/6J mice when administered subcutaneously or orally.
- **Although the Farias-Eisner Laboratory focused on ovarian cancer, we postulated that apoA-I, apoE, and apoJ and the associated functional chimera mimetic peptides will become a novel class of anti-angiogenesis and anti-inflammatory agents used for therapies in a number of diseases whose etiology is governed by angiogenesis and inflammation, including cancer.**
(Vasquez SX, Gao F, Su F, Grijalva V, Pope J, Bill Martin B, Stinstra J, Masner M, Shah N, Weinstein DM, Reddy ST, **Farias-Eisner R.** MicroCT Imaging and Blood Vessel Diameter Quantitation of Preclinical Mouse Specimen Vasculature with Radiopaque Silicone Polymer Injection Medium, ***PLoS One***. 2011 Apr 18; 6(4): e19099. PMCID: PMC3078938)
(Ganapathy E, Meriwether D, Su F, Grijalva V, Devarajan A, Gao F, Chattopadhyay A, Reddy ST, **Farias-Eisner R**, D-4F, an apoA-I mimetic peptide, inhibits proliferation and viability of epithelial ovarian cancer cells by upregulating the anti-oxidant enzyme MnSOD, ***Int J Cancer***. 2012 Mar 1; 130(5): 1071-81 PMCID: PMC3248802)

(JG, White M, Cruz A, **Farias-Eisner R**. In 2014, can we do better than CA125 in the early detection of ovarian cancer? ***World J Biol Chem***. 2014 Aug 26; 5(3): 286-300. PMCID: PMC4160523)
(Su F, Spee C, Araujo E, Barron E, Wang M, Ghione C, Hinton DR, Nusinowitz S, Kannan R, Reddy ST, **Farias-Eisner R.** A Novel HDL-Mimetic Peptide HM-10/10 Protects RPE and Photoreceptors in Murine Models of Retinal Degeneration, ***Int J Mol Sci***. 2019 Sep 27;20(19):4807. doi: 10.3390/ijms20194807.PMID: 31569695)
(Su F, Anantharamaiah GM, Mayakonda N, Palgunachari C, White R, Stessman H, Wu Y, Vadgama V, Pietras R, Nguyen D, Reddy ST, Farias-Eisner R. Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice. **J Cancer Res Therap Oncol** 2020 8: 1-15. *in press*)

The Farias-Eisner Laboratory then turned its attention and focus to determining the molecular mechanism(s) responsible for the anti-tumorigenic efficacy of the HDL/apoA-1 functional mimetic peptides; the Farias-Eisner Laboratory became the first to report that L-5F, an apolipoprotein A-I mimetic, inhibited tumor angiogenesis by suppressing VEGF / basic FGF signaling pathways.

- Studies were designed to examine whether inhibition of angiogenesis is one of the mechanisms for the observed anti-tumorigenic effects.
- The apoA-I mimetic peptide L-5F inhibited VEGF- and bFGF-induced activation of their corresponding receptors, VEGFR2 and FGFR1, as well as downstream signaling pathways, including Akt and ERK1/2. MicroCT scanning and immunohistochemistry staining demonstrated that L-5F decreased both the quantity and size of tumor vessels in mice.
- **Our data that L-5F inhibits angiogenesis suggests that apoA-I mimetic peptides may serve as novel anti-angiogenesis agents for the treatment of angiogenesis-associated diseases, including cancer.**
- **Most recently, US, and International Patents have been issued for the "use" and "composition of matter" (sequence) of these highly effective novel molecules for the prevention and treatment of pro-inflammatory diseases.**
  (Farias-Eisner G, Su F, Robins T, Kotlerman J, Reddy S, **Farias-Eisner R**, Validation of serum biomarkers for detection of early-stage and late-stage endometrial cancer. ***Am J Obstet Gynecol*****,** Sep 19, 2009. PMID: 19285648)
  (Vasquez SX, Gao F, Su F, Grijalva V, Pope J, Bill Martin B, Stinstra J, Masner M, Shah N, Weinstein DM, Reddy ST, **Farias-Eisner R**. MicroCT Imaging and Blood Vessel Diameter Quantitation of Preclinical Mouse Specimen Vasculature with Radiopaque Silicone Polymer Injection Medium, ***PLoS One*****.** 2011 Apr 18; 6(4): e19099.5. PMCID: PMC3078938)

The Farias-Eisner Laboratory then turned its attention and focus to determining whether HDL mimetics would inhibit tumor

development in other adenocarcinoma organ types; including both induced and spontaneous mouse models of colon cancer.

- Recent studies suggested that high-density lipoprotein (HDL) levels are inversely related to colon cancer risk.
- HDL mimetics constructed from a number of peptides and proteins with varying structures possess anti-inflammatory and antioxidant properties reminiscent of HDL.
- We examined whether HDL mimetics, affect tumor growth and development in mouse models of colon cancer. HDL mimetics reduced viability and proliferation of CT26 cells, a mouse colon adenocarcinoma cell line, and decreased CT26 cell-mediated tumor burden in BALB/c mice when administered subcutaneously or orally. Our results, for the first time, identified HDL mimetics as a novel therapeutic strategy for the treatment of colon cancer.
- **The Farias-Eisner Laboratory is the first to report the identification and characterization of highly effective novel HDL functional chimera mimetic peptides for the treatment of pro-inflammatory diseases, including ovarian, and now colon cancer.**
- **Most recently, US and International Patents have been issued for the use of these highly effective novel molecules for the prevention and treatment of pro-inflammatory diseases.**
  (Memarzadeh S, Kozak KR, Chang L, Natarajan S, Shintaku P, Reddy ST, **Farias-Eisner R,** Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer. ***Proc Natl Acad Sci U S A,*** 6; 99(16): 10647-52, 2002.)
  (Memarzadeh S, Holschneider C, Bristow R, Jones N, Fu YS, Karlan BY, Berek JS, **Farias-Eisner R**, FIGO Stage III and IV Uterine Papillary Serous Carcinoma: Impact of Residual Disease on Survival. ***Int J Gynecol Cancer*** 12(5): 454-8, 2002.)
  (Gao F, Chattopadhyay A, Navab M, Grijalva V, Su F, Fogelman AM, Reddy ST, **Farias-Eisner R**. Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1α in human ovarian cancer cell lines and a mouse ovarian cancer model., ***J Pharmacol Exp Ther***. 2012 Aug; 342(2): 255-62. PMCID: PMC3400800)

APPENDIX M

PHILANTHROPY AND FUND RAISING – DGSOM AND CUSOM

Development Program – Department of Obstetrics and Gynecology

- Established a multimillion-dollar Development Program for the Department of Obstetrics and Gynecology;
- Created a highly successful Capital Development Program network for the Department of Obstetrics and Gynecology, through the effective cultivation of individual donors, corporations, and foundations with a tailored approach to philanthropic giving;
- Generated an individualized, donor-centered, approach to capital development that spanned over a decade of fund-raising realizations for the department, and shaped a leadership, and pioneering role in development which significantly and positively impacted the careers of junior, intermediate, and senior faculty; the academic careers of which were mentored, nurtured, and supported through personalized targeted philanthropy;
- Planned and executed major, and yet discreet, fundraising campaigns, successfully. Assumed responsibility for managing a broad array of successful fundraising departmental programs, shaped by innovation and creativity in achieving effective results through a unique personalized approach to philanthropy that has become a model system;
- Leadership style that resulted in the expansion of the department fundraising capacity, in multiple areas, while growing the Capital Development Program to include special focus on donor relations and stewardship, scholarship fundraising, online giving and championing the conversion of a database gift accounting system to a constituent relationship management system;
- The collective result of these and many other leadership efforts, large and small, resulted in record-setting fundraising at the departmental level.
- Founded and currently directs a Comprehensive multimillion-dollar Philanthropic Capital Development Program for the Department of Obstetrics and Gynecology;
- Established and managed a robust and diverse Philanthropic Capital Development portfolio at the intersection of seemingly diverse academic disciplines;
- Expanded the level of extra-mural funding, while focusing on career development and advancement of junior, mid-level, and senior faculty in various Divisions and Departments;
- Established an effective philanthropic initiative comprised of grateful patients, for various Divisions and Departments;
- Laid the philanthropic groundwork for recently designated Women's and Children Tower at the Ronald Reagan Medical Center (RRMC);
- Currently raising funds for an Institute for Women's Reproductive Health and Women's Cancer Research through a strategic recruitment and program development network, for the Department of ObGyn

APPENDIX N

FARIAS-EISNER RESEARCH LABORATORY - ENTREPRENEURIAL AND FUNDING SUCCESS – DGSOM AND CUSOM

Founding Director, Comprehensive, NIH/NCI funded, Farias-Eisner Research Laboratory: Center for Biomarker Discovery, and Women's Cancer Research DGSOM AND CUSOM
(2000-present)

- **The Farias-Eisner Research Laboratory** is a dedicated center of research excellence for medical and molecular research and education; supporting women's reproductive health, including successful and productive clinical, translational, and basic science research programs;
- The Farias-Eisner Laboratory has enjoyed a successful Diagnostic Biomarker Discovery Program and a successful Novel Targeted Therapy Discovery Program; both of which have resulted in the filing and publishing of numerous Domestic and International Patents, in partnership with the Regents of the University of California.
- Result: robust and diverse research portfolio at the intersection of seemingly diverse academic disciplines;
- Expanded level of extra-mural funding, while focusing on career development and advancement of junior and mid-level faculty in various Divisions and Departments;
- The aforementioned Center fosters inter-dependent research, and training opportunities. Investigator-initiated Clinical Trials Program UCLA-Farias-Eisner (Principal Investigator): Clinical Trials Program dedicated to the study of the novel HDL/apoA-1/apoE/apoJ Functional Chimera Mimetic Peptides identified, characterized, and validated in the Farias-Eisner Laboratory.
- This unique program has initiated and completed the pre-IND process toward the establishment of three Double-Blind, Randomized, Placebo-Controlled, Parallel Group Dose-Range Exploration Pilot Phase-1 Trials to evaluate three novel HDL/apoA-1/apoE/apoJ Functional Chimera Mimetic Peptides. Salvaregen, LLC (Farias-Eisner co-founded in partnership with the University of California) is the source of funding.
- Intellectual Property and Commercialization: OVA1 is an FDA-cleared* blood test (2009), developed in the Farias-Eisner Laboratory, the Intellectual Property filed by the Regents of the University of California on behalf of the Farias-Eisner Laboratory, to help evaluate an ovarian mass, and to help the Primary Care Physician distinguish benign from malignant, prior to referral to the Gynecologic Oncologist for a planned surgery.
- It has subsequently been commercialized by Quest Laboratories 2010), with the support of the University of California and the Farias-Eisner Laboratory.
- The Farias-Eisner Laboratory/University of California Regents, has US and international patent interests, for critical diagnostic assays, and for the chemical composition, and use, of novel therapeutic molecules:

HDL/apoA-1/apoE/apoJ Functional Chimera Mimetic Peptides for the Prevention and Treatment of Pro-Inflammatory conditions: U.S. and International patent applications (e.g. US, Canada, European Union, Australia, Japan, China, India) have been filed for the use of diagnostic, and novel therapeutic molecules (e.g. functional mimetic peptides), for the prevention and treatment of pro-inflammatory conditions (e.g. Cancer), as well as other functional mimetic chimera peptides in our library, will qualify for accelerated regulatory approval, which will enable drugs developed from these peptides to come to commercialization sooner.

APPENDIX O

OTHER PROFESSIONAL ACTIVITIES (SELECTED)

Principal Investigator, NRG –National Research Group, Program, at DGSOM (NCI27469-22) and CUSOM
(2014–present)

- Established the NIH/NCI NRG, at UCLA; the NRG was recently created by the NCI, to bring together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).
- Created the NRG Oncology coalition at UCLA, that conducts practice defining, multi-institutional clinical trials resulting in the improved survival and quality of life of patients with cancer;
- The major goal of this project is to conduct clinical trials designed for the detection, prevention and treatment of gynecologic malignancies; in addition, the NRG Oncology Program emphasizes other gender-specific malignancies, including breast, and prostate cancers, and on localized or locally advanced cancers of all types.
- Established a leadership role for UCLA in the NRG enterprise; thus, delivering to UCLA more than 150 years' cumulative experience in conducting practice-defining, multi-institutional phase II and III trials sponsored primarily by the NCI;
- Instituted a network of Principal Investigators so that the emphasis on the seven major cancer subtypes, at UCLA, will complement the research missions and clinical trial portfolios of the other groups within the National Cancer Trials Network (NCTN);
- Initiated, at UCLA, a gender-specific cancer program, with a focus on patients with localized and intermediate-stage malignancies, an emphasis that is relevant to all seven of NRG Oncology's cancer disease sites.

APPENDIX P

OTHER NON-EMPLOYER ACTIVITIES AND ACCOMPLISHMENTS - NATIONAL ORGANIZATIONS

- NIH Study Section; NIH/NICHD-OPRC; RFA-HD-14-013; U54 study section
- American Board of Emergency Medicine
- American Board of Obstetrics & Gynecology
- American Subspecialty Board in Gynecologic Oncology
- American Board of Surgery
- Molecular Biology Institute – UCLA
- Society of Gynecologic Oncology

APPENDIX Q

PROFILE

- This profile highlights extensive experience in the creation of successful academic departmental, school of medicine, university and national programs utilizing an academic leadership skill set, developed over a 30-year period, based upon certain valued traits that I highly value: integrity, character, trust, transparency, compassion, fairness, humility, team-driven principles, mentoring-driven ideals, diversity, inclusivity, and communication.
- The application of these skills has resulted in the creation of team-driven, innovative, and highly successful academic Healthcare programs, promoting national and international preeminence for the academic Healthcare Enterprise at DGSOM and CUSOM.

BACKGROUND

- I began my scientific career as a STAR (Specialty Training in Advanced Research) graduate/fellow, a PhD program at the Molecular Biology Institute at UCLA, designed for clinician-scientists that have an aptitude for basic science research (Molecular Biology).
- Over the two past decades, my Laboratory has focused on the identification, characterization, and validation of differentially expressed proteins that serve as biomarkers of early stage ovarian cancer, and the development of related new and novel anti-cancer drugs.
- We developed an effective panel of biomarkers for the early detection of ovarian cancer, which was FDA approved for clinic use in 9/2009; we were issued the US and European Patent for this Intellectual Property in 2009, and Quest Laboratories has licensed the use of these markers from the University of California and has distributed the commercial product, MIA (Multivariate Index Assay-OVA1 plus) internationally.
- Four clinical trials have demonstrated that the novel and highly accurate diagnostic platform effectively differentiates a benign from malignant ovarian mass, and hence can be utilized to assist the primary care physician in deciding whether to refer the patient to a Gynecologic Oncologist.
- This led to our serendipitous discovery that apoA-I, a biomarker for the detection of early stage ovarian cancer and the major constituent of HDL, and the related apoA-1 mimetic peptide, is a putative novel therapeutic agent for the treatment of devasting proinflammatory diseases (e.g. cancer, atherosclerosis, Alzheimer's disease, Age-Macular Degeneration).
- Although our initial studies were focused on ovarian cancer, we postulated that apoA-I and its functional mimetic peptides will become a novel class of anti-angiogenesis and anti-inflammatory agents used for therapies in a number of diseases whose etiology is governed by angiogenesis and inflammation, including cancer.
- The Farias-Eisner Laboratory is the first to report the identification and characterization of highly effective novel HDL functional chimera

mimetic peptides (e.g. HM1010, AEM) for the prevention and treatment of pro-inflammatory diseases, including cancer, atherosclerosis, Alzheimer's disease, Age-Macular Degeneration. Most recently, US and International Patents for the "Use" and "Composition of Matter" (Sequence) have been issued for these highly effective novel molecules for the prevention and treatment of these devastating pro-inflammatory diseases, including cancer.

RECENT ACADEMIC AWARDS AT DGSOM AND CUSOM

Recognition within the academic Healthcare system includes:

1) **Serge & Yvette Dadone Clinical Teaching Award** (2011), at the DGSOM, recognizing outstanding dedication, innovation, and sustained excellence in clinical and classroom teaching;
2) **Sherman M. Mellinkoff Dean's Award** (2012), at the DGSOM which represents the greatest honor of recognition from the DGSOM Dean's Office, at UCLA, and bestowed annually upon a Faculty member, clinician-scientist-educator whose teaching, integrity, and character exemplifies the best in the art of medicine and the finest in doctor-patient relationships. Only 31 clinician-scientists have received the coveted award since its inception in 1981.
3) **The Charles F. and Mary C. Heider Endowed Chair in Cancer Research** at the CUSOM and Creighton University represents the late Henry Lynch MD a world-renowned pioneer in hereditary cancer detection and prevention who died in June, founded Creighton's Hereditary Cancer Center and was the inaugural holder of the Charles F. and Mary C. Heider Endowed Chair in Cancer Research. The Heider Endowed Chair in Cancer Research was established in 2004, through the generosity of alumni and benefactor Charles "Charlie" Heider, BSC'49, HON'10, and his wife, Mary. The coveted Heider Endowed Chair in Cancer Research award is committed to support the discovery of novel predictors of pro-inflammatory diseases, including cancer, and to the development of novel new drugs.

MISSION AND VISION AT DGSOM AND CUSOM

- My mission and vision have been to promote women's health on all academic levels
- To build successful programs in order to achieve clinical, research, and educational excellence, to establish effective business and entrepreneurial academic models of excellence, eliminate healthcare disparities, and promote the basic values of honesty, compassion and integrity in all programs that we build at DGSOM and CUSOM.

SUCCESSFUL EXECUTION OF THE ACADEMIC HEALTHCARE SYSTEM MISSION AND VISION AT DGSOM AND CUSOM

- We have fulfilled the mission and vision of the academic Healthcare system at DGSOM at UCLA, and more recently, at CUSOM and CHI Health; and to have led the respective Departments through the ever-

changing national Healthcare environ, as vice Chair and Chair, respectively.

- As a committed clinician-scientist-educator, and experienced academician, I share in the DGSOM at UCLA, and more recently, CUSOM and CHI Health, enterprise mission, vision, and values, and to have effectively executed the principles inherent to the mission and vison, for the respective Departments of Obstetrics and Gynecology.
- As a Surgeon-Scientist-Educator, I have created successful academic departmental programs applying certain coveted valued human traits including integrity, character, trust, transparency, compassion, fairness, humility, team-driven principles, mentoring-driven ideals, diversity, inclusivity, and communication.
- I have effectively navigated the current global business-driven academic Healthcare system enterprise space, within the healthcare industry arena. I have learned the importance of a team-driven and innovative model that encourages creativity to achieve highly successful academic Healthcare programs, promoting national and international preeminence for the Healthcare enterprise.

EXAMPLES OF EXECUTION OF THE MISSION AND VISION AT DGSOM AND CUSOM

- The creation of NIH and non-NIH funding,
- The establishment of robust mentoring programs for the resident and fellow Trainees,
- The building of robust mentoring programs for the faculty,
- The retention and recruitment of high-quality faculty,
- The construction of nationally recognized residency and fellowship training programs in all subspecialties,
- The promotion of Clinical, Research, and Educational Centers of Excellence
- The creation of robust and sustainable business models for excellence in the clinical, research, and educational arenas, and to effectively engage the community, and creation of strong development programs,
- The establishment of strong nurturing environments of academic excellence, business, and entrepreneurial success that have led to a trajectory of national preeminence.

SUCCESSFUL KEY ACADEMIC PROGRAMS AT DGSOM AND CUSOM

HIGHLIGHTS OF OUR SUCCESSES IN BUSINESS, ENTREPRENEURIAL, CLINICAL, RESEARCH, EDUCATIONAL, AND COMMUNITY ENGAGEMENT PROGRAMS OF EXCELLENCE AT DGSOM AND CUSOM

- The academic-business model that we established over the past three decades, for the DGSOM and now the CUSOM, is an internationally recognized exemplary enterprise of academic excellence and scholastic success.

- The endpoint achieved is a highly innovative, robust, and sustainable, academic integrated Healthcare system, positioning the Department of Obstetrics and Gynecology, in step with the School of Medicine, the University, and national programs.
- The success of the academic enterprise spanning the three decades, provided me with a deep understanding of the essential components required to create a value-based high-quality Healthcare department enterprise with opportunities for faculty and staff, alike.
- The profile highlights department academic programs established, at DGSOM and CUSOM, for the Department of Obstetrics and Gynecology, and for the School of Medicine, included a variety of highly successful clinical, research, educational, and entrepreneurial business-driven projects:
- Discoveries at the research bench in the Farias-Eisner Laboratory (e.g. Center for Biomarker Discovery, and Women's Cancer Research)
  Lead to valued intellectual property for the University of California, in which Multivariate Index Assay (MIA/OVA1), a highly effective marker for ovarian cancer, utilized clinically to differentiate a benign from malignant ovarian neoplasm, commercialized by Quest Laboratories, was identified, characterized, validated, and commercialized in partnership with the University.
- The assay is used worldwide. This novel and highly accurate diagnostic platform in so effectively differentiating a benign from malignant ovarian mass, can be utilized to assist the primary care physician in deciding whether to refer the patient to a Gynecologic Oncologist.
- Third year clerkship for Gynecology - Medical Student Program - Director
- Sub-Intern clerkship for Gynecology Oncology - Medical Student Program - Director
- Resident Trainee Program - RRC Committee
- Fellowship Training Program– Gynecologic Oncology – Director
- Development Programs – Community Engagement – Director
- NIH U54 Awards – Elimination of Health Care Disparities - Principal Investigator
- Department Quality Assurance, Morbidity and Mortality, and Improvement Programs -
- Programs to create Centers of Clinical excellence, Research and Educational excellence

OUR SPIRIT OF INNOVATION, CREATIVITY, COMMITMENT AND DEDICATION HAS CATAPULTED OUR ACADEMIC HEALTHCARE ENTERPRISE FOR WOMEN TO NATIONAL AND INTERNATIONAL PREEMINENCE AT DGSOM AND CUSOM

- Programs established at DGSOM and CUSOM creating national prototypes of academic excellence in Women's Health:
- Creation of centers of excellence in clinical, research, education, and community engagement. Our intrepid spirit of academic adventure has

resulted in an integrated Health Care System founded with high academic distinction.

SUCCESSES IN NAVIGATING THE CURRENT GLOBAL HEALTHCARE SPACE FOR WOMEN'S HEALTH ATTRIBUTED TO TRAINING AND EXPERIENCE – DGSOM AND CUSOM

- Unique training as a Surgeon-Scientist-Educator (e.g. Professor Researcher-Educator, Molecular Biologist, Critical Care Medicine subspecialist, Obstetrics and Gynecology, Gynecologic Oncologist),
- A strong and greater than 30-year experience as an Administrator (e.g. National Board Examiner; PI NIH/NCI U54 program; PI National Research Group; Department of Obstetrics and Gynecology, Vice Chair, Administration, Chief, Gynecologic Oncology), and
- Trained to lead an academic business-clinical-research-educational enterprise, and achieve unprecedented preeminence in this space, nationally and internationally.

TRACK RECORD OF EXCELLENCE AT DGSOM AND CUSOM

- A record of innovative strategic and operational leadership, in collaboration with enterprise leadership,
- A record, at DGSOM and CUSOM, of visionary leadership in step with the institutional goals to advance innovative, and cutting-edge obstetrics and gynecology clinical, research, and educational programs of excellence,
- A strong commitment to advance patient care and scholarly quality,
- A record of successful strategic and fiscal oversight of the clinical, research, educational, and community outreach programs of excellence,
- A strong record of evidence-based medicine programs that advance Quality Assurance, patient safety, high performance, Quality Improvement, risk management, and efficient resource utilization,
- A strong record for executing a successful team-driven, trust-building, transparency-based, patient-centered, communicative, and collaborative leadership model,
- A successful record of accepting accountability for the clinical and academic performance of all divisions as Vice Chair, Administration and Interim Chair,
- A strong record for positive, collegial relationships among Chairs, Chiefs, and Medical Directors at DGSOM and CUSOM,
- A successful record at DGSOM and CUSOM for strategic leadership, direction, and coordination of all Departmental clinical, research, and educational aspects in step with Enterprise leadership goals,
- A strong record at DGSOM and CUSOM of delivering the highest possible quality of healthcare in an environment of growing volume,
- A strong reputation for high quality academic leadership, fostering an environment of high integrity, character, trust, transparency, cooperation, communication, collegiality, nurturing, mentoring, and powerful vision, for the Department, and its faculty,
- A successful record of inter-departmental collaboration, departmental

growth, a robust vision for the future, the creation of innovative clinical programs, and strong visible leadership and mentorship,
- A proven track record at DGSOM and CUSOM, as an effective manager of faculty and voluntary physician staff, and medical support staff, in the highly competitive healthcare Los Angeles market, and the success at administering the financial and business affairs of the department,
- A strong record at administering the department's academic success with the highest ethical behaviors, exemplary business standards, and fostering a value of human diversity and includes all people in a meaningful contribution to organizational success,
- A successful record at administrating an Envisioning Strategy, Engaging People, Executing to Achieve Results, Strategic and Visionary Leadership, Matrixed Leadership, and Collaboration skills,
- A proven record for excellent leadership, communication, and interpersonal skills, coupled with a broad, contemporary market insight,
- A successful ability to focus upon the current status, trends, and outlook to create a high-quality healthcare enterprise delivery system, with a solid grasp of healthcare finance and the ability to effectively participate in strategic planning and program development initiatives,
- Experience developing academic leaders and a reputation for mentorship and development and retention of junior faculty, as well as intermediate, and senior faculty,
- An expertise in understanding contemporary Healthcare markets with a focus upon the current status, trends, and outlook for a complex Health Care delivery system within the obstetrics and gynecology space. Demonstrates an understanding of the Accountable Care Organizations (ACO) environments and value-based patient-centered care,
- A strong record in working within a multi-hospital integrated delivery system, with concomitant understanding of the complexities of managing across a new and growing system of care to create a robust academic department enterprise,
- An expertise in the successful identification, recruitment, mentorship, and development of academic and non-academic physicians, and
- An established record in working with private, as well as voluntary, medical staff members.

EDUCATION PROGRAMS OF EXCELLENCE AT DGSOM AND CUSOM

NOVEL EDUCATIONAL PROGRAMS AT DGSOM AMD CUSOM

- All five of the Obstetrics and Gynecology subspecialty fellowship programs transitioned from ABOG to ACGME oversight in June, 2017.
- As the Program Director for the newly created Gynecologic Oncology UCLA/OVMC Fellowship training program, my role not only included the successful oversight of the team creating the new ACGME accredited Gynecologic Oncology Fellowship Training Program, at DGSOM, but I was also instrumental in administrative oversight of all of the fellowship programs transitioning to ACGME.

- I have initiated a similar initiative at CUSOM in order to establish subspecialty care.

APPENDIX R

DEVELOPMENT PROGRAMS AT DGSOM AND CUSOM

SUCCESSFUL COMMUNITY ENGAGEMENT AND DEVELOPMENT PROGRAMS AT DGSOM AND CUSOM

- For over 3 decades, I have dedicated my efforts to the establishment of a well-respected Community Engagement and Development Program for the Department of Obstetrics and Gynecology at DGSOM and now CUSOM.
- The Department Faculty and their respective collaborators have benefited immensely from my development activities at DGSOM.
- The successful fund-raising efforts have resulted in the support and mentorship of countless junior, intermediate, and senior faculty for their clinical, research, and educational projects.

APPENDIX S

ACADEMIC EXECUTIVE TIMELINE SUMMARY

PROFESSIONAL EDUCATION, APPOINTMENTS, CERTIFICATIONS, AND SELECTED AWARDS/ HONORS

- **1976: UCLA**/Albright College, LA, CA & Reading, PA – B.S. Biochemistry;

- **1981**: **Royal College of Surgeons**, Dublin, Ireland - M.D., LRSCI;

- **1984**: **Residency Training Program:** Emergency Medicine/Critical CareUniversity of Illinois/University of Chicago; Chicago, Illinois;

- **1984: Chief Resident - Residency Training Program:** Emergency Medicine/Critical Care; University of Illinois/University of Chicago; Chicago, Illinois;

- **1985: Faculty - Residency Training Program:** Emergency Medicine/Critical Care; University of Illinois/University of Chicago; Chicago, Illinois;

- **1986: Residency Training Program:** Obstetrics and Gynecology; UCLA School of Medicine; Department of Obstetrics and Gynecology; Los Angeles, California;

- **1986: American Board of Emergency Medicine Certification;**

- **1990: Chief Resident - Residency Training Program:** Obstetrics and Gynecology; UCLA School of Medicine; Department of Obstetrics and Gynecology; Los Angeles, California;

- **1991: Faculty:** Department of Obstetrics and Gynecology/Gynecologic Oncology, at UCLA

- **1991: Assistant Professor** - FTE (Academic Series) Department of Obstetrics and Gynecology
  David Geffen School of Medicine at UCLA (DGSOM);

- **1992: Fellow Training Program:** Gynecologic Oncology; UCLA School of Medicine; Department of Obstetrics and Gynecology; Los Angeles, California;

- **1993: American Board of Obstetrics and Gynecology Certification**

- **1993: Allegra Charach Memorial Fund Award**

- **1993: UCLA Academic Senate Award**

- **1994: Jonsson Business-Educational Enterprise Award**

- **1995: Director:** Gynecologic Oncology at the Greater Los Angeles Health Care System; UCLA-Westside Veteran Administration Hospital

- **1995: American Cancer Society Award**

- **1995 – present: UCLA Department of Obstetrics and Gynecology – Faculty Teaching Awards at UCLA**; Faculty Outstanding Teaching Awards in Obstetrics & Gynecology; Los Angeles, California (10 awards over 12 years)

- **1997: American Board of Obstetrics and Gynecology - Subspecialty Gynecologic Oncology Certification**

- **1999: STAR (Specialty Training in Advanced Research): PhD Program – Molecular Biology;** Molecular Biology Institute at UCLA; Los Angeles, California

- **2000: The Joan English Fund for Women's Cancer Research Award/Trustee**

- **2001: NIH: WRHL Award**

- **2000: Associate Professor** - FTE (Academic Series) Department of Obstetrics and Gynecology David Geffen School of Medicine at UCLA (DGSOM)

- **2001: NIH-R03 Independent Investigator Award**

- **2001: Liz Tilberis Ovarian Cancer Scholar Independent Investigator Award**

- **2004: Jonsson Business-Educational Enterprise Independent Investigator (Stranahan)**

- **2004: Step-up Foundation Award**

- **2004: Translational Research Award**
- The International Spirit of Life Foundation (ISOLF) - Scientist of the Year Award

- **2004: Translational Research Award**

The Step-Up Foundation - Translational Research Scientist Award

- **2004: Faculty Executive Committee at UCLA**

- **2005: Professor** - FTE (Academic Series) Department of Obstetrics and Gynecology David Geffen School of Medicine at UCLA (DGSOM)

- **2005: Associate Director** Women's Cancer Program for the Jonsson Comprehensive Business-Educational Enterprise at UCLA

- **2005: Director: Gynecologic Oncology at UCLA**

- **2005: Associate Director** Gynecologic Oncology Fellowship Training Program/Selection Committee

- **2005: Quality Assurance** Committee: Department Obstetrics and Gynecology

- **2005: Chair - Multidisciplinary Tumor Board Conference**

- **2005: Department of Veteran Affairs MERIT 1 (RO1 Equivalent) Grant Award (Principal Investigator)**

- **2005: Faculty Teaching - National Award**
  National APGO Outstanding Faculty Teaching Award

- **2005 – present: American Board of Obstetrics and Gynecology**
  Written Board Examiner (Contributor of written questions) and Oral Board Examiner

- **2005 – present: American Board of Obstetrics and Gynecology – Gynecologic Oncology;** Written Board Examiner (Contributor of written questions)

- **2005 – present: American Board of General Surgery**
  Written Board Examiner (Contributor of written questions)

- **2005 – present: American Board of Emergency Medicine**
  Written Board Examiner (Contributor of written questions)

- **2005: Institutional Research Review Board** Committee (VA- west LA)

- **2005: Chair -** Multidisciplinary Tumor Board Conference - UCLA

- **2006: K12/K30 Clinical Pharmacology Award**

- **2007: NIH – RO1 Award– (co-Investigator)**

- **2010: Society of Gynecologic Oncologist: Vice Chair – Membership Committee**

- **2010: Kelly Day Foundation Award**

- **2010 - present: Farah Fawcett Foundation Award**

- **2010 - present: Stark Family Foundation Award**

- **2010 - present: Carl and Roberta Deutsch Foundation Award**

- **2011: Serge & Yvette Dadone Clinical Teaching Award**
  Distinguished Recipient 2011- David Geffen School of Medicine at UCLA**;**
  outstanding dedication, innovation, and sustained excellence in clinical and classroom teaching - exceptional educator.

- **2012: Sherman M. Mellinkoff Dean's Award**
  Distinguished Recipient 2012- David Geffen School of Medicine at UCLA
  Clinician-scientist-educator-entrepreneur;
  exemplifies the best of the best in the art of medicine and the finest in doctor-patient relationships.

- **2012: Society of Gynecologic Oncologist: Chair – Membership Committee**

- **2012: NIH/NCI – U54 – Multicenter Award (Principal Investigator)**

- **2013: Chair - Sherman M. Mellinkoff Dean's Award Committee**

- **2015: Professor** – Step VI (Step VII pending); FTE (academic series)**;** Department of Obstetrics and Gynecology**;** David Geffen School of Medicine (DGSOM)**;**

- **2015: NIH/NCI – U54 – Multicenter Award (Principal Investigator)**

- **2015 – present:** U54 Award – Co-Chair; NIH Study Section **-** NIH/NICHD-OPRC; RFA-HD-14-013

- **2015: Masters in Business Administration (MBA):** Graziadio School of Business management; Pepperdine University; Los Angeles, California

- **2015: Investigator-initiated clinical trials program; UCLA-Farias-Eisner (Principal Investigator)** Double-Blind, Randomized, Placebo-Controlled, Parallel Group Dose-Range Exploration Pilot Studies to evaluate the novel HDL/apoA-1/apoE/apoJ Functional Chimera Mimetic Peptides-Farias-Eisner Laboratory identified novel molecules. Salvaregen (Farias-Eisner co-founder) funded.

- **2015: Program Director** Gynecologic Oncology Fellowship UCLA/OVMC
  Training Program/Selection Committee

- **2019: Professor and Chair** - Department of Obstetrics and Gynecology at Creighton University School of Medicine (CUSOM)

- **2019: Associate Dean Women's Health** at the CUSOM

- **2019: Director, Hereditary Cancer Center** at the CUSOM

- **2019: Charles F. and Mary C. Heider Endowed Chair in Cancer Research** - Creighton University - CUSOM

APPENDIX T

LECTURES AND PRESENTATIONS

1. **"Synchronous Primary Neoplasms of the Female Reproductive Tract"**. Presented at the Western Association of Gynecologic Oncologists - May, 1988.

2. **"Cytoreductive Surgery for Advanced Ovarian Cancer: Cardiovascular Evaluation Pulmonary Artery Catheters"**. Presented at the Western Association of Gynecologic Oncologists, San Francisco, CA - May, 1989.

3. **"ITP in Pregnancy: Mode of Delivery, Literature Review, Quality Assurance"**. Presented at the UCLA School of Medicine, Department of Obstetrics and Gynecology, April, 1990.

4. **ACLS (Advanced Cardiac Life Support) Course**, Northwestern University, School of Medicine, Obstetrics and Gynecology Housestaff, Chicago, IL - May, 1990.

5. **National ACOG - Stump the Professor Case**, Atlanta, GA - May, 1990.

6. **"Cytoreductive Surgery for Advanced Ovarian Cancer: Cardiovascular Evaluation with Pulmonary Artery Catheters"**; Chief Resident's Thesis -- Presented at the UCLA School of Medicine, Department of Obstetrics and Gynecology, Los Angeles, CA - June, 1990.

7. **"Second-Look Laparoscopy Revisited"**. Presented at the Western Association of Gynecologic Oncologists, Newport Beach, CA - 1991.

8. **"Adjuvant Radiation Therapy After Radical Hysterectomy for Stage I-B 'High Risk' Cervical Cancer"**; Presented at the Western Association of Gynecologic Oncologists, Tamara, CO - 1992.

9. **"Conservative and Individualized Surgery in Early Stage (T_{1-2}, N_{0-1}, M_0) Vulvar Cancer"**. Presented at the Western Association of Gynecological Oncologists, Tamara, CO - 1992.

10. **"The Influence of Tumor Number, Size, and Distribution After Optimal (<5 mm) Primary Cytoreductive Surgery for Epithelial Ovarian Cancer"**. Presented at the Western Association of Gynecologic Oncologists, Tamara, CO - 1992.

11. **"Influence of Tumor Number, Size, Distribution and Grade After Optimal (<5 mm) Primary Cytoreductive Surgery for Epithelial Ovarian Cancer"** Presented at the Annual Meeting the Society of Gynecologic Oncology, Palm Springs, CA -- February, 1993.

12. **"Conservative and Individualized Surgery in Early Stage (T_{1-2}, N_{0-1}, M_0) Vulvar Cancer"** Presented at the Annual Meeting of the Society of Gynecologic Oncology, Palm Springs, CA - February, 1993.

13. **"The Role of Adjuvant Radiation Therapy for ≤3 Microscopic Positive Pelvic Lymph Nodes Following Radical Hysterectomy for Stage Ib Cervical Cancer"** Presented at the International Gynecologic Cancer Society - Biennial Meeting, Stockholm, Sweden -- August, 1993.

14. **"Conservative and Individualized Surgery in Early Stage (T_{1-2}, N_{0-1}, M_0) Vulvar Cancer"** Presented at the International Gynecologic Cancer Society Biennial Meeting, Stockholm, Sweden -- August, 1993.

15. **"Nitric Oxide is an Important Mediator for Tumoricidal Activity in Vivo."** Poster presentation at the Society for Gynecologic Investigation -- Chicago, Illinois, March, 1994.

16. **"Nitric Oxide: Cytotoxic Effector Molecule in Human Epithelial Ovarian Cancer."** Poster presentation at the Society for Gynecologic Investigation -- Chicago, Illinois, March, 1995.

17. **"The Cloning of Genes Causal in Cell Differentiation."** Multidisciplinary Research Symposium, UCLA Department of Obstetrics and Gynecology -- Los Angeles, CA, February, 1996.

18. **"The Mechanism of NO-Mediated Tumoricidal Activity In-Vitro."** Presented at the International Helene Harris Memorial Meeting -- Los Angeles, CA , May, 1997.

19. **"Does O-linked N-acetylglucosamine (O-GlcNAc) glycosylation at Thr58 of the human c-myc protein play a role in c-myc mediated transcriptional regulation and cellular transformation in rat 1A?"** Presented at the UCLA Molecular Biology Institute Oral Qualifying Examination, Los Angeles, CA – January, 1999.

20. **"The Molecular Mechanism of Neurotrophin-directed cellular differentiation."** Presented at the UCLA Molecular Biology Institute group intralaboratory meeting, Los Angeles, CA – January, 1999.

21. **"The Molecular Mechanism of Neurotrophin-directed cellular differentiation."** Presented at the UCLA Molecular Biology Institute third floor interlaboratory meeting, Los Angeles, CA – March, 1999.

22. **"The Molecular Mechanism of Neurotrophin-directed cellular differentiation."** Presented at the UCLA Molecular Biology Institute third floor interlaboratory meeting, Los Angeles, CA – March, 2000.

23. **"The Molecular Mechanism of Neurotrophin-directed cellular differentiation."** Presented at the UCLA Biological Chemistry Lake Arrowhead retreat, Lake Arrowhead, CA – April, 2000.

24. **"The Expression of Urokinase Plasminogen Activator Receptor (UPAR) in Endometrial Cancer."** Poster presentation at the Society of Gynecologic Oncologists, Phoenix, Arizona - March, 2001.

25. **"Identification of Biomarkers for Women's Cancer using Transcription and Protein Profiling: Potential Use in Diagnosis and Prognosis."** Oral presentation. Dan Morton Society, Department of Obstetrics and Gynecology, Los Angeles, California - June, 2002.

26. **"Identification of Biomarkers for Women's Cancer using Transcription and Protein Profiling: Potential Use in Diagnosis and Prognosis."** Grand Rounds, Department of Obstetrics and Gynecology, Los Angeles, California - September, 2002.

27. **"Identification of Biomarkers for Women's Cancer using Transcription and Protein Profiling: Potential Use in Diagnosis and Prognosis."** Grand Rounds, Department of Obstetrics and Gynecology, Los Angeles, California - September, 2003 **.**

28. **"Identification of Biomarkers for Women's Cancer using Transcription and Protein Profiling: Potential Use in Diagnosis and Prognosis."** Oral presentation. Dan Morton Society, Department of Obstetrics and Gynecology, Los Angeles, California - June, 2003.

29. **"Identification of Biomarkers for Ovarian Cancer using Strong Anion-Exchange ProteinChips: Potential Use in Diagnosis and Prognosis."** Poster presentation at the Conference on Proteomics (HUPO meeting), Montreal, Canada - September, 2003

30. **"Identification of Biomarkers for Women's Cancer using Transcription and Protein Profiling: Potential Use in Diagnosis and Prognosis."** Oral presentation at the National Alliance of Ovarian Cancer research, San Francisco, California - September, 2003.

31. **"Identification of Biomarkers for Ovarian Cancer using Strong Anion-Exchange ProteinChips: Potential Use in Diagnosis and Prognosis."** Poster presentation at the Conference on Human Proteome Organization, Montreal, Canada - September, 2003.

32. **"Characterization of Biomarkers for the Early Detection of Ovarian Cancer"**; presentation at the awards ceremony for the International Spirit of Life Foundation Scientist of the year award; Four Season's Hotel, Beverly Hills , Ca, - May, 2004.

33. **"Identification and Characterization of Biomarkers for the Early Detection of Ovarian Cancer";** Johnson Comprehensive Cancer Center collaborative conference UCLA/DREW University Research Project; King/DREW University, L.A., Ca, - May, 2004.

34. **"Identification of the *CIS*-acting Elements of the Rat UPAR Promoter that Modulate NGF-induced UPAR Expression in PC12 cells";** UCLA Molecular Biology Institute, L.A., Ca, - May, 2004.

35. **"Characterization of the *CIS*-acting Elements of the Rat UPAR Promoter that Modulate NGF-induced UPAR Expression in PC12 cells";** UCLA Department of Obstetrics and Gynecology grand rounds, L.A., Ca, - May, 2004.

36. **"Characterization of Biomarkers for Ovarian Cancer using Strong Anion-Exchange Protein Chips: Use in Diagnosis and Prognosis."** Invited speaker: **I**nternational Conference on Human Proteomics; Tokyo, Japan - May, 2004.

37. **"Oxidative Stress and Pro-inflammatory Signals: a Permissive Environment for the Malignant Transformation to Ovarian Cancer."** Invited speaker: XVth Annual Ovarian Cancer Workshop, Vancouver, British Columbia; July, 2004.

38. **"Characterization of Biomarkers for Ovarian Cancer using Strong Anion-Exchange Protein Chips: Use in Diagnosis and Prognosis."** Oral presentation at the Conference on Proteomics (HUPO meeting), Invited Speaker, University of Tokyo; Tokyo, Japan - May, 2004.

39. **"Characterization of Biomarkers for Ovarian Cancer using Strong Anion-Exchange Protein Chips: Use in Diagnosis and Prognosis."** University of Florida Cancer Center; June, 2004.

40. **"Oxidative Stress and Pro-inflammatory Signals: a Permissive Environment for the Malignant Transformation to Ovarian Cancer."** Keynote speaker at the XVth Annual Ovarian Cancer Workshop, Vancouver, British Columbia; July, 2004.

41. **"Oxidative Stress and Pro-inflammatory Signals Create a Permissive Environment for the Malignant Transformation."** Molecular Imaging Conference, Orlando, Florida; March, 2005.

42. **"The Early Detection of Ovarian Cancer: The Development of a Hand Held Device Utilizing Nanotechnology."** Resident Day Visiting Professor Presentation. Department of Obstetrics and Gynecology, UCLA, L.A., California; June, 2005.

43. **"Characterization of Biomarkers for Ovarian Cancer using Strong Anion-Exchange Protein Chips: Use in Diagnosis and Prognosis."** Grand Rounds, Department of Obstetrics and Gynecology, UCLA, L.A., California; September, 2005.

44. **"Characterization of Biomarkers for Ovarian Cancer using Strong Anion-Exchange Protein Chips: Use in Diagnosis and Prognosis."** Keynote Speaker; panel discussion, Departments of Medicine and Surgery, City of Hope National Cancer Center, Duarte, California; September, 2005.

45. **"The Early Detection of Women's Cancer: The Development of a Hand Held Device Utilizing Nanotechnology."** Clinical and Translational Research Symposium, Invited Speaker. 5th annual City of Hope Women's Cancer Conference, Las Vegas, Nevada; November, 2005.

46. **"Surgical Diseases in pregnancy".** Surgical Grand Rounds, Invited Speaker, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, November, 2005.

47. **"The Early Detection of Ovarian Cancer: The Development of a Hand Held Device Utilizing Nanotechnology."** Presentation Step-Up Foundation, David Geffen School of Medicine at UCLA, Los Angeles, California, November, 2005.

48. **"Tumor Markers in Gynecologic Cancers"** Presentation at the Los Angeles Obstetrics and Gynecology Society Annual Assembly – Invited Speaker; Pasadena Hilton, California, February, 2006.

49. **"Where is Research Going in Gynecologic Cancer"** Presentation at the Los Angeles Obstetrics and Gynecology Society Annual Assembly – Invited Speaker; Pasadena Hilton, California, February, 2006

50. **"Imaging in Gynecologic Cancers"** Presentation at the Los Angeles Obstetrics and Gynecology Society Annual Assembly – Invited Speaker; Pasadena Hilton, California, February, 2006.

51. **"HPV management in the young women"** Presentation at the Los Angeles Obstetrics and Gynecology Society Annual Assembly – Invited Speaker; Pasadena Hilton, California, February, 2006.

52. **"Robotic Surgery in Gynecology and Gynecologic Oncology"** Presentation at the Los Angeles Obstetrics and Gynecology Society Annual Assembly – Invited Speaker; Pasadena Hilton, California February, 2006.

53. **"The Cloning and Characterization of the Rat Urokinase Plasminogen Activator Receptor Promoter in PC12 Cells"** Presentation Step-Up Foundation, David Geffen School of Medicine at UCLA, Los Angeles, California, March, 2006.

54. "**The Early Detection of Women's Cancer: the Development of a Hand Held Device Utilizing Nanotechnology",** Grand Rounds, Harbor-UCLA, Department of Obstetrics and Gynecology, UCLA, Los Angeles, California, March, 2006.

55. **"Gynecologic Cancers: Update Immunologic Therapy and Vaccines",** Saul Raniweiz lecture JCCC, Jules Stein, UCLA, Los Angeles, California, August, 2006.

56. **"Ovarian Cancer and Cervical Cancer Treatment Update: Current Debates",** Seminar, Multidisciplinary Oncology Seminar Beverly Hills, California, August, 2006.

57. **"Ovarian Cancer Treatment Update: Current Debates",** Grand Rounds, UCLA, Department of Obstetrics and Gynecology, UCLA, Los Angeles, California, September, 2006.

58. **"The Early Detection of Ovarian Cancer: the Role for Nanotechnology"** Endocrine Grand Rounds Lecture, Department of Medicine, UCLA, Los Angeles, California, September, 2006.

59. **"Ovarian Cancer and Cervical Cancer Treatment Update: Current Debates",** Seminar, Stanford Medical Oncologist Forum, Santa Rosa, California, October, 2006.

60. **"Ovarian Cancer Treatment Update: Current Debates",** Seminar, Santa Monica-UCLA, Medical Oncologist Forum, Los Angeles, California, November, 2006.

61. **"The Characterization of a Biomarker Panel for the Early Detection of Ovarian Cancer"** Visiting Professor presentation to Salvatore Moncada, Department of Obstetrics and Gynecology, UCLA, Los Angeles, California, November, 2006.

62. **"Altered Hemoglobin associated with High Density Lipoproteins in Sera from Mice Fed Atherogenic/Hyperlipidemic Diets"** Presented at the American Heart Association. Chicago, Illinois, November, 2006.

63. **"D-4F Treatment Decreases the Association of Altered Hemoglobin and its Scavengers with High Density Lipoprotein in Mice"** Presented at the American Heart Association. Chicago, Illinois, November, 2006.

64. **"Protein Profiling of Serum and Density Lipoprotein in Mice Fed Atherogenic/Hyperlipidemic Diets"** Presented at the American Heart Association. Chicago, Illinois, November, 2006.

65. **"The Identification and Characterization of a Biomarker Panel for the Early Detection of Ovarian Cancer"** Round Table Discussant, Center for Hepato-Billiary Diseases, Villejuif (Paris), France, November, 2006.

66. **"Ovarian Cancer and Cervical Cancer Treatment Update: Current Debates",** Medical Oncology Seminar Beverly Hills, California, December, 2006.

67. **"The Identification and Characterization of a Biomarker Panel for the Early Detection of Ovarian Cancer"** oral presentation (Society for Gynecologic Oncology) SGO annual meeting, San Diego, California, March, 2007.

68. **"ApoA1: a putative target for early stage ovarian cancer therapy"** oral presentation (American Society for Clinical Pharmacology Therapeutics) ASCPT annual meeting, Anaheim, California, March, 2007.

69. **"Minimally Invasive Surgery: Gynecologic Robotic Surgery"** oral presentation, University of Illinois, Chicago, Illinois, April, 2007.

70. **"Ovarian Cancer Treatment Update: Current Debates, and Anticoagulation Therapy in the Cancer Patient ",** Multidisciplinary Oncology Seminar- Honolulu, Hawaii, June, 2007.

71. **"Identification and Management of patients with the BRCA 1&2 Mutation Deletion"** oral presentation, Resident Teaching Rounds, UCLA, Department of Obstetrics and Gynecology, Los Angeles, California, September, 2007.

72. **"Ovarian Cancer Treatment Update: Current Debates, and Anticoagulation Therapy in the Cancer Patient",** Multidisciplinary Oncology Seminar- Las Vegas, Nevada, October, 2007.

73. **"HPV Prevention and Management-update in the young women",** Multidisciplinary Oncology Seminar- Beverly Hills, California, October, 2007.

74. **"The Prevention and Treatment of Thromboembolic Events in the Surgical Patient"**, Multidisciplinary Oncology Seminar-Medical Oncology, oral presentation, UCLA, Los Angeles, California, January, 2008.

75. **"HPV Prevention and Management-update in the young women",** Multidisciplinary Primary Care; Seminar, Phoenix, Arizona, February, 2008.

76. **"Ovarian Cancer Treatment Update: Current Debates, and Anticoagulation Therapy in the Cancer Patient",** Multidisciplinary Oncology Seminar-Medical Oncology, oral presentation, Phoenix, Arizona, March, 2008.

77. **"Hormone Replacement Therapy: the risk for a gynecologic cancer."** Multidisciplinary Oncology Seminar-Medical Oncology, oral presentation, Los Angeles, California, March, 2008.

78. **"The Prevention and Treatment of Thromboembolic Events in the Surgical Patient"**, Multidisciplinary Oncology Seminar-Medical Oncology, oral presentation, East Carolina University, Greenville, North Carolina, April, 2008.

79. **"Putative Therapeutic Targets for the treatment of Early Stage Ovarian Cancer"** Round Table Discussant, Duke University, Durham, North Carolina, May, 2008.

80. **"Identification and Management of patients with the BRCA 1&2 Mutation Deletion"** oral presentation, Resident Reaching Rounds, UCLA, Department of Obstetrics and Gynecology, Los Angeles, California, June, 2008.

81. **"Putative Therapeutic Targets for the treatment of Early Stage Ovarian Cancer"** Grand Rounds, keynote speaker, 3rd Annual OB/GYN Symposium, Texas Tech University, El Paso, Texas, August, 2008

82. **"Ovarian Cancer Treatment Update: Current Debates, and Anticoagulation Therapy in the Cancer Patient",** Multidisciplinary Oncology Seminar-Medical Oncology, oral presentation, Phoenix, Arizona, October, 2008.

83. **"ApoA1: a putative target for early stage ovarian cancer therapy"** oral presentation (American Society for Clinical Pharmacology Therapeutics) ASCPT annual meeting, Anaheim, California, December, 2008.

84. **"ApoA1: a putative target for ovarian cancer therapy"** oral presentation, Floor meeting UCLA, Department of Obstetrics and Gynecology, Los Angeles, California, December, 2008.

85. **"Identification and Management of patients with the BRCA 1&2 Mutation Deletion"** oral presentation, Resident Rounds, UCLA, Department of Obstetrics and Gynecology, Los Angeles, California, January, 2009.

86. **"HPV Prevention and Management-update in the young women",** Multidisciplinary Primary Care; University of Arizona, Seminar, Phoenix, Arizona, January, 2009.

87. **"ApoA1: a putative target for early stage ovarian cancer therapy"** oral presentation (American Society for Clinical Pharmacology Therapeutics) ASCPT annual meeting, Anaheim, California, February, 2009.

88. **"Applied Anatomy of the Abdomen and Pelvis: the key to Gynecologic and Gynecologic Oncology surgery",** oral presentation, UCLA, Medical Student Lecture, February, 2009.

89. **"Applied Anatomy of the Abdomen and Pelvis: the key to Gynecologic and Gynecologic Oncology surgery",** oral presentation, UCLA Resident Lecture, March, 2009.

90. **"Post-operative ileus in Gynecologic and Gynecologic Oncology surgery",** oral presentation, OB/GYN/Gyn Onc/General Surgery Resident and Fellow lecture Seminar, UCLA Los Angeles, California, May, 2009.

91. **Therapeutic Targets for the treatment of Endometrial Cancer"** Resident Rounds, UCLA, Department of Obstetrics and Gynecology, Los Angeles, California, May, 2009.

92. **"ApoA1: a putative target for early stage ovarian cancer therapy"** oral presentation, SPORE Grant Consortium Meeting, NCI, Rockville, Maryland, June, 2009.

93. **"Therapeutic Targets for the prevention and treatment of Ovarian Cancer"** Grand Rounds, keynote speaker, Florida Society of Gynecologic Oncologists, Long Boat, Florida, June, 2009.

94. **"ApoA1: a putative target for early stage ovarian cancer therapy"** oral presentation, SPORE Grant Consortium Meeting, Yale University, New Haven, Connecticut, July, 2009.

95. **"The differential expression of specific gene clusters may be used as prognostic indicators of poorly differentiated gynecologic cancers",** poster presentation, STTP Medical Student Mentor Program, David Geffen School of Medicine at UCLA, Los Angeles, California, August, 2009.

96. **"The prevention and treatment of post-operative ileus in Gynecologic and Gynecologic Oncology surgery",** oral presentation, colorectal surgical symposium, University of Texas, Dallas, Texas August, 2009.

97. **"Ovarian Cancer Treatment Update: Current Debates, and Anticoagulation Therapy in the Cancer Patient",** Multidisciplinary Oncology Seminar - Moffitt Cancer Center, keynote speaker, Tampa, Florida, September, 2009.

98. **"Minimally Invasive Surgery: Gynecologic and Gynecologic Oncology Robotic Surgery", oral presentation,** UCLA, Department of Obstetrics and Gynecology, Los Angeles, California, Resident Rounds, September, 2009.

99. **"Therapeutic Targets for the prevention and treatment of Endometrial and Ovarian Cancer". University of Southern California, Research Symposium –** Los Angeles, California, September, 2009.

100. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a novel therapy for chemotherapy-resistant ovarian cancer".** Research Seminar, New Haven, CT, February, 2010.

101. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a novel therapy for chemotherapy-resistant ovarian cancer".** Research Seminar, New Haven, CT, April, 2010.

102. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a novel therapy for chemotherapy-resistant ovarian cancer".** Research Seminar, Department of Medicine, Atherosclerosis Research Program, David Geffen School of Medicine at UCLA, Los Angeles, California, June, 2010.

103. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a novel therapeutic approach to treatment of recurrent chemotherapy-resistant ovarian cancer".** Symposium, New Haven, CT, August, 2010.

104. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a novel therapy for chemotherapy-resistant ovarian cancer".** Research Symposium, Ronald Reagan Medical Center Board of Trustees at UCLA, Los Angeles, California, October, 2010.

105. **"Ovarian Cancer Biomarkers: Evaluation and Treatment of the Pelvic Mass ."** Yale University Ella Grasso Annual Visiting Professor Lecture and Symposium – New Haven, CT, November, 2010.

106. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a diagnostic and therapeutic Role for Ovarian Cancer."** L.A. BioMed. Harbor-UCLA –Torrance, CA, December, 2010.

107. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a diagnostic and therapeutic Role for Ovarian Cancer."** K30 Research Symposium, Gonda Research Building at UCLA, Los Angeles, California, December, 2010.

108. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a therapeutic Role for adenocarcinoma of the ovary and colon."** Women's Endowment Board, Los Angeles, California, January, 2011.

109. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a therapeutic Role for adenocarcinoma of the ovary and colon."** L.A. BioMed Members, Harbor-UCLA, Los Angeles, California, January, 2011.

110. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a therapeutic Role for adenocarcinoma of the ovary and colon."** L.A. BioMed Board of trustees; Harbor-UCLA, Los Angeles, California, February, 2011.

111. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a therapeutic Role for adenocarcinoma of the ovary and colon."** JCCC Seminar Series; UCLA, Los Angeles, California, March, 2011.

112. **"HPV: A Global Epidemic – Prevention."** UCLA, Resident Lecture Series; UCLA, Los Angeles, California, May, 2011.

113. **"Early detection of ovarian cancer by Apolipoprotein A-I (apoA-I); and apoA-I and its mimetic peptides: a therapeutic Role for adenocarcinoma of the ovary."** University of Kentucky, Nixon Lectureship**;** Louisville, Kentucky, Sept, 2011.

114. **"HPV: A Global Epidemic – Prevention."** UCLA, K30 Lecture Series; UCLA, Los Angeles, California, December, 2011.

115. **"CREOG Review Series – Gynecologic Pre-Invasive and Gynecologic Oncology Staging."** UCLA CREOG Review Series; UCLA, Los Angeles, California, January, 2012.

116. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a therapeutic Role for adenocarcinoma of the ovary and colon."** Gynecology/Gynecologic Oncology Team Educational Series; UCLA, Los Angeles, California, March, 2012.

117. **"HDL/apoA-I mimetic peptides: Role in the prevention and treatment of pro-inflammatory conditions"** Teaching Rounds Series; UCLA, Los Angeles, California, May 2012.

118. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a therapeutic Role for adenocarcinoma of the ovary and colon."** Reddy Laboratory Seminar Series; UCLA, Los Angeles, California, June, 2012.

119. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a therapeutic Role for adenocarcinoma of the ovary and colon."** Farias-Eisner Laboratory Seminar Series; UCLA, Los Angeles, California, July, 2012.

120. **"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides: a therapeutic Role for adenocarcinoma of the ovary and colon."** Pfeizer: Research and Development Conference; UCLA, Los Angeles, California, August, 2012.

121. **"HDL/apoA-I mimetic peptides: Role in the prevention and treatment of pro-inflammatory conditions."** Translational Research Intellectual Property Review; UCLA, Los Angeles, California, October, 2012.

122. **"HDL/apoA-I mimetic peptides: Role in the prevention and treatment of pro-inflammatory conditions."** Farias-Eisner Laboratory Seminar; UCLA, Los Angeles, California, November, 2012.

123. **"HPV: A Global Epidemic – Prevention."** UCLA, K30 Lecture Series; UCLA, Los Angeles, California, December 2012.

124. **"ApoA-I functional mimetic peptides: the treatment of pro-inflammatory conditions."** Pfeizer: Research and Development Conference; UCLA, Los Angeles, California, December, 2012.

125. **"HDL/apoA-I mimetic peptides: Role in the prevention and treatment of pro-inflammatory conditions."** Research and Development Seminar; UCLA, Los Angeles, California, January, 2013.

126. **"HDL functional mimetic peptides: the treatment of epithelial cancers (e.g. ovarian and colon)."** U54 NIH Oversight Committee Conference; UCLA, Los Angeles, California, February, 2013.

127. **"ApoA-I mimetic peptides: a novel treatment for cancer of the ovary, uterus, and colon."** M253 Seminar; UCLA, Los Angeles, California, June, 2013.

128. **"Novel targeted therapies for the treatment of gynecologic malignancies."** Gynecologic Oncology teaching rounds; UCLA, Los Angeles, California, August, 2013.

129. **"Functional mimetic peptides: a new model for the prevention and treatment of pro-inflammatory conditions."** Research Donor's retreat and seminar; Bel Air, California, August, 2013.

130. **"HDL and apoA-I functional mimetic peptides: effective treatment of gynecologic malignancies."** Gynecologic Oncology teaching Seminar; UCLA, Los Angeles, California, September, 2013.

131. **"ApoA-I and bHDL biologic functional mimetic peptides: Role in the prevention and treatment of pro-inflammatory conditions."** Farias-Eisner Laboratory Seminar; UCLA, Los Angeles, California, October, 2013.

132. **"Novel therapies for the treatment of ovarian cancers."** Research Donor's ; UCLA, Los Angeles, California, November, 2013.

133. **"HDL/apoA-I functional mimetic peptides: Role in the prevention and treatment of pro-inflammatory conditions."** Research Donor's Seminar; UCLA, Los Angeles, California, December, 2013.

134. **"HDL functional mimetic peptides: Role in the treatment of ovarian and colon cancer."** Research Donor's Seminar; Bel Air, California, January, 2014.

135. **"Novel therapies for the treatment of epithelial cancers."** Research Donor's retreat; Bel Air, California, February, 2014.

136. **"HDL/apoA-I functional mimetic peptides: Role in the prevention and treatment of pro-inflammatory conditions (e.g. Cancer, Alzheimer's disease)."** Research and Investor's Seminar; Bel Air, California, March, 2014.

137. **"Novel therapies for the treatment of epithelial cancers."** Farrah Fawcett Foundation seminar; Farrah Fawcett Los Angeles, California, March, 2014.

138. **"From the bedside to the bench".** Carl and Roberta Deutsch Foundation seminar; Carl and Roberta Deutsch Foundation, Los Angeles, California, April, 2014.

139. **"From the bedside to the bench".** Carl and Roberta Deutsch Foundation seminar; Carl and Roberta Deutsch Foundation, Los Angeles, California, June, 2014.

140. **"From the bedside to the bench".** Farrah Fawcett Foundation seminar; Farrah Fawcett foundation; Los Angeles, California, August, 2014.

141. **"From the bedside to the bench".** Carl and Roberta Deutsch Foundation seminar; Carl and Roberta Deutsch Foundation, Los Angeles, California, September, 2014.

142. **"From the bedside to the bench".** Department of Obstetrics and Gynecology; Grand Rounds; David Geffen School of Medicine at UCLA, Los Angeles, California, October, 2014.

143. **Investor-Initiated Clinical Trials: Closing the Health Disparities' Gap in Cancer Care; Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries;** Department of Obstetrics and Gynecology; Grand Rounds; David Geffen School of Medicine at UCLA, Los Angeles, California, December, 2014.

144. **"Investigator-Initiated Clinical Trials".** Department of Obstetrics and Gynecology; Resident Teaching Rounds; David Geffen School of Medicine at UCLA, Los Angeles, California, January, 2015.

145. **"Investigator-Initiated Clinical Trials".** Carl and Roberta Deutsch Foundation seminar; Carl and Roberta Deutsch Foundation, Los Angeles, California, March 2015.

146. **"UPDATE: PART II Novel Diagnostic and Therapeutic Discoveries; new data**
Progress"; Department of Obstetrics and Gynecology; Grand Rounds; David Geffen School of Medicine at UCLA, Los Angeles, California, August, 2015.

147. **"Novel Diagnostic Platform";** Department of Obstetrics and Gynecology; Grand Rounds; David Geffen School of Medicine at UCLA, Los Angeles, California, January, 2016.

148. **"Investigator-Initiated Clinical Trials".** Carl Deutsch Philanthropist discussion; Carl and Roberta Deutsch Foundation, Los Angeles, California, March 2016.

149. **"Investigator-Initiated Clinical Trials".** Carl Deutsch Philanthropist discussion; Carl and Roberta Deutsch Foundation, Los Angeles, California, June 2016.

150. **"Investigator-Initiated Clinical Trials".** Carl and Roberta Deutsch Foundation seminar; Carl and Roberta Deutsch Foundation, Los Angeles, California, July, 2016.

151. **"Closing the Health Disparities' Gap in Cancer Care; Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries";** Department of Obstetrics and Gynecology; University of Toledo, August, 2016.

152. **"Closing the Health Disparities' Gap in Cancer Care; Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries";** Department of Obstetrics and Gynecology; Rutgers Robert Wood Johnson Medical School, August, 2016.

153. **"Closing the Health Disparities' Gap in Cancer Care; Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries";** Department of Obstetrics and Gynecology; Texas Tech Medical School, El Paso; September, 2016.

154. **"Novel Diagnostic Platform";** Department of Obstetrics and Gynecology; Grand Rounds; David Geffen School of Medicine at UCLA, Los Angeles, California, January, 2016.

155. **"Investigator-Initiated Clinical Trials".** Carl Deutsch Philanthropist discussion; Carl and Roberta Deutsch Foundation, Los Angeles, California, March 2016.

156. **"Investigator-Initiated Clinical Trials".** Carl Deutsch Philanthropist discussion; Carl and Roberta Deutsch Foundation, Los Angeles, California, June 2016.

157. **"Investigator-Initiated Clinical Trials".** Carl and Roberta Deutsch Foundation seminar; Carl and Roberta Deutsch Foundation, Los Angeles, California, July, 2016.

158. **"A Business-Driven Academic Healthcare System Enterprise Model of Academic Excellence";** Department of Obstetrics and Gynecology; University of Toledo, August, 2016.

159. **"Closing the Health Disparities' Gap in Cancer Care; Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries";** Department of Obstetrics and Gynecology; Rutgers Robert Wood Johnson Medical School, August, 2016.

160. **"Closing the Health Disparities' Gap in Cancer Care; Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries";** Department of Obstetrics and Gynecology; Texas Tech Medical School, El Paso; September, 2016.

161. **"Elimination of Healthcare Disparities in a Cancer Cohort - Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries";** U54 IAC oversight committee; UCLA, February, 2017.

162. **"Elimination of Healthcare Disparities in a Cancer Cohort - Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries";** U54 NCI oversight committee; UCLA, April, 2017.

163. **"A Business-Driven Academic Healthcare System Enterprise Model of Academic Excellence";** Department of Obstetrics and Gynecology; Rutgers Robert Wood Johnson Medical School, June, 2017.

164. **"Investigator-Initiated Clinical Trials".** Carl and Roberta Deutsch Foundation seminar; Carl and Roberta Deutsch Foundation, Los Angeles, California, July, 2017.

165. **"A Business-Driven Academic Healthcare System Enterprise Model of Academic Excellence";** Department of Obstetrics and Gynecology; Texas Tech Medical School, El Paso; September, 2017.

166. **"A Business-Driven Academic Healthcare System Enterprise Model of Academic Excellence";** Department of Obstetrics and Gynecology; University of Utah Medical School, Salt Lake City; November, 2017.

167. **"A Business-Driven Academic Healthcare System Enterprise Model of Academic Excellence";** American Hospital of Paris, Paris; March, 2018.

168. **"A Business-Driven Academic Healthcare System Enterprise Model of Academic Excellence";** Department of Obstetrics and Gynecology; UNLV Medical School, Las Vegas; March, 2018.

169. **Elimination of Healthcare Disparities in a Cancer Cohort - Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries;** U54 NCI oversight IAC committee; UCLA, July, 2018.

170. **Elimination of Healthcare Disparities in a Cancer Cohort - Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries;** U54 NCI oversight PACHE committee; UCLA, August, 2018.

171. **Elimination of Healthcare Disparities in a Cancer Cohort - Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries;** U54 NCI oversight IAC committee; UCLA, January, 2019.

172. **Elimination of Healthcare Disparities in a Cancer Cohort - Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries;** U54 NCI oversight PACHE committee; UCLA, January, 2019.

173. **Elimination of Healthcare Disparities in a Cancer Cohort - Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries;** U54 NCI oversight IAC committee; UCLA, March, 2019.

174. **Elimination of Healthcare Disparities in a Cancer Cohort - Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries;** U54 NCI oversight PACHE committee; UCLA, April, 2019.

175. **Elimination of Healthcare Disparities in a Cancer Cohort - Direct Clinical Applications of Novel Diagnostic and Therapeutic Discoveries;** U54 NCI oversight IAC committee; UCLA, March, 2019.

176. **Discoveries: From the Research Bench to the Patient Bedside;** Resident Research Day; Department of Obstetrics and Gynecology; Creighton University School of Medicine; Creighton University; June, 2019.

177. **Ureteric Injuries in Obstetrics and Gynecology;** Grand Rounds; Department of Obstetrics and Gynecology; Creighton University School of Medicine; Creighton University July, 2019.

178. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; July, 2019.

179. **Comprehensive Review 1: Medical Student Didactic**; Creighton University School of Medicine; Creighton University; August, 2019.

180. **Comprehensive Review 2: Medical Student Didactic**; Creighton University School of Medicine; Creighton University; August, 2019.

181. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; August, 2019.

182. **Blood Supply to the Pelvis – Applied Anatomy and Clinical Implications**; Grand Rounds; Department of Obstetrics and Gynecology; Creighton University School of Medicine; Creighton University; August, 2019.

183. **Rosie, the Orangutan – an Emergency Surgical Case - Comparative Care and Applied Anatomy: Orangutan vs Homo Sapiens**; Grand Rounds; Department of Obstetrics and Gynecology; Creighton University School of Medicine; Creighton University; Sept, 2019.

184. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; September, 2019.

185. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; October, 2019.

186. **Comprehensive Review 1: Medical Student Didactic**; Creighton University School of Medicine; Creighton University; November, 2019.

187. **Comprehensive Review 2: Medical Student Didactic**; Creighton University School of Medicine; Creighton University; November, 2019.

188. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; November, 2020.

189. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; December, 2019.

190. **Endometrial Cancer – American Board of Obstetrics and Gynecology (ABOG) – Update**; Grand Rounds; Department of Obstetrics

and Gynecology; Creighton University School of Medicine; Creighton University; January, 2020.

191. **Comprehensive Review 1: Medical Student Didactic**; Creighton University School of Medicine; Creighton University; January, 2020.

192. **Comprehensive Review 2: Medical Student Didactic**; Creighton University School of Medicine; Creighton University; January, 2020.

193. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; January, 2020.

194. **Comprehensive Review 1: Medical Student Didactic**; Creighton University School of Medicine; Creighton University; February, 2020.

195. **Comprehensive Review 2: Medical Student Didactic**; Creighton University School of Medicine; Creighton University; February, 2020.

196. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; February, 2020.

197. **Blood Supply to the Pelvis – Applied Anatomy and Clinical Implications**; Medical Student Didactic lecture; Creighton University School of Medicine; Creighton University; March, 2020.

198. **Small Group Research Strategy 1: Medical Student**; Creighton University School of Medicine; Creighton University; March, 2020.

199. **Small Group Research Strategy 2: Medical Student**; Creighton University School of Medicine; Creighton University; March, 2020.

200. **Small Group Research Strategy 3: Medical Student**; Creighton University School of Medicine; Creighton University; March, 2020.

201. **Small Group Research Strategy 4: Medical Student**; Creighton University School of Medicine; Creighton University; March, 2020.

202. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; March, 2020.

203. **Small Group Research Strategy 1: Medical Student**; Creighton University School of Medicine; Creighton University; April, 2020.

204. **Small Group Research Strategy 2: Medical Student**; Creighton University School of Medicine; Creighton University; April, 2020.

205. **Small Group Research Strategy 3: Medical Student**; Creighton University School of Medicine; Creighton University; April, 2020.

206. **Small Group Research Strategy 4: Medical Student**; Creighton University School of Medicine; Creighton University; April, 2020.

207. **Blood Supply to the Pelvis – Applied Anatomy and Clinical Implications**; Medical Student Didactic lecture; Creighton University School of Medicine; Creighton University; April, 2020.

208. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; April, 2020.

209. **Small Group Research Strategy 1: Medical Student**; Creighton University School of Medicine; Creighton University; May, 2020.

210. **Small Group Research Strategy 2: Medical Student**; Creighton University School of Medicine; Creighton University; May, 2020.

211. **Small Group Research Strategy 3: Medical Student**; Creighton University School of Medicine; Creighton University; May, 2020.

212. **Small Group Research Strategy 4: Medical Student**; Creighton University School of Medicine; Creighton University; May, 2020.

213. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; May, 2020.

214. **Small Group Research Strategy 1: Medical Student**; Creighton University School of Medicine; Creighton University; June, 2020.

215. **Small Group Research Strategy 2: Medical Student**; Creighton University School of Medicine; Creighton University; June, 2020.

216. **Small Group Research Strategy 3: Medical Student**; Creighton University School of Medicine; Creighton University; June, 2020.

217. **Small Group Research Strategy 4: Medical Student**; Creighton University School of Medicine; Creighton University; June, 2020.

218. **Elimination of Healthcare Disparities in a Cancer Cohort –** U54 NCI strategic planning; June, 2020.

219. **Introduction to Oncology –** Physician Assistant Program, June, 2020

220. **Gynecologic Oncology –** Physician Assistant Program, June, 2020

221. **Discoveries: From the Research Bench to the Patient Bedside –** Physician Assistant Program, June, 2020

222. **Discoveries: From the Research Bench to the Patient Bedside –** Visiting Professor – Resident Graduation Day – Phoenix, Arizona June, 2020